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CHAPTER 1
GENERAL BACKGROUND

1. a. Introduction to hypertension
Cardiovascular disease is the leading single cause of death in the US1. One of
the most important risk factors for cardiovascular disease is hypertension which is
present in about 30% of the U.S. population2. Although great advances have been
made in the treatment of high blood pressure, about 20% of hypertensive people do not
respond to treatment3. Thus, it is important to continue to investigate the mechanisms
that mediate hypertension.
The kidneys play an important role in regulating blood pressure by adjusting Na
and water reabsorption and thus affecting extracellular fluid volume. Guyton showed
that increases in blood pressure result in increases in Na and water excretion by the
kidney by a mechanism called pressure-natriuresis. When the kidney cannot properly
eliminate an excess of Na, extracellular body fluid augments and so does blood
pressure, therefore inducing natriuresis and returning blood pressure to basal levels.
Thus, Guyton established that sustained elevations in blood pressure are the
consequence of an impaired ability of the kidney to excrete an excess of Na and water
and concluded that hypertension can only occur in the presence of impaired pressurenatriuresis4. Therefore, studying the mechanisms that contribute to inappropriately
enhanced NaCl reabsorption by the kidney during hypertension could help elucidate
new targets for the treatment of high blood pressure.

1. b. Thick ascending limb transport
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The thick ascending limb of the loop of Henle (THAL) is a nephron segment that
has been shown to participate in blood pressure regulation5. It reabsorbs 20 to 30 % of
the filtered NaCl load and is characterized by its ability to transport NaCl independently
of water, thus generating transepithelial NaCl gradients of up to 120 mEq/L and
contributing to the cortico-medullary osmotic gradient6. The THAL’s ability to dilute
intratubular fluid is not only important in NaCl reabsorption but also in water
reabsorption. By generating hypotonic tubular fluid, the THAL allows for vasopressinstimulated water reabsorption by the distal tubule and the cortical collecting duct to take
place. Given that the reabsorptive capability of the downstream portions of the nephron
is limited, inhibition of THAL’s NaCl transport results in profuse diuresis, natriuresis and
in reduction of blood pressure as seen after treatment with loop diuretics such as
furosemide.
NaCl reabsorption by the THAL occurs via transcellular and paracellular
pathways (Figure 1); however, transcellular reabsorption drives paracellular ion
transport and thus inhibition of the former inevitably results in blockade of the latter7. In
the THAL, Na entry across the luminal membrane is carried out by 2 main transporters:
Na/K/2Cl cotransporter type 2 (NKCC2)8 and Na/H exchanger (NHE3)9. NKCC2 activity
accounts for 80% and NHE3 20%of transcellular Na transport. Na exits the cell via the
Na/K ATPase pump. Cl is transported out by the basolateral Cl channels (in particular
ClC NKB)
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and K/Cl cotransporters (mainly KCC4)11. Finally, K exits through both

luminal and basolateral K channels (including the renal outer medullary K channel or
ROMK)

12-15

and through the basolateral K/Cl cotransporters. K recycling to the lumen

is not only important for NKCC2 to function, but also contributes to generation of a
lumen positive transepithelial potential which generates the driving force for the
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paracellular transport of cations including Na, Ca and Mg.
The role the THAL plays in regulating blood pressure is underscored by the
effectiveness of furosemide in decreasing blood pressure16, by the hypotension
observed in Bartter syndrome17 where THAL NaCl transport is impaired, and by the
enhanced THAL NaCl reabsorption observed in salt-sensitive hypertension5,18-20. In
Dahl-salt sensitive rats, a model of salt-sensitve hypertension, Cl reabsorption by the
THAL is enhanced18-20 and decreases in NO-mediated inhibition of NaCl reabsorption21,
increases in superoxide formation22 and elevation in NKCC2 levels23 have been shown
to play a role.

Therefore, studying the signaling mechanisms that affect NaCl

reabsorption by the THAL is important in understanding blood pressure regulation.
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Figure 1. Overview of THAL ion transport. Schematic representation of THAL cells and
ion transporters, see explanation in the text.
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1. c. Angiotensin II and NO: two important regulators of blood pressure and renal
function
Angiotensin II (Ang II) is a key regulator of blood pressure through its actions on
the kidneys24-28, blood vessels29, heart30 and central nervous system31. Most of its prohypertensive actions are mediated by Ang II receptor type 1 (AT1)32. The role of Ang II
in blood pressure regulation is underscored by the broad utilization of renin
inhibitors33,34, angiotensin I converting enzyme blockers35,36 and AT1 receptor
antagonists37,38 in the treatment of human hypertension.
Chronic infusion of Ang II in rodents has been extensively used as a model of
hypertension39-42. In this model, the kidneys play an important role as shown by the
decreased elevation in blood pressure observed in WT mice transplanted with kidneys
from AT1 knockout mice24. Although many studies have explored the contribution of
different renal structures in Ang II-induced hypertension40,43-46, the role of THALs in this
model is still not completely understood.
Acutely, Ang II has a biphasic effect on THAL ion transport: at concentrations of
1 pmol/L or lower Ang II inhibits whereas at 1 µmol/L Ang II stimulates NKCC2 activity47.
Interestingly, Ang II levels in the kidney are in the nanomolar range and they increase
further in response to chronic Ang II infusion48 suggesting that NKCC2 activity is likely to
be increased during hypertension.

Ang II also stimulates the 10-ps Cl channel in

THALs49 as well as increases superoxide production and protein kinase C (PKC)
activity50, which stimulate NKCC2 activity and NaCl reabsorption by the THAL51-53.
Finally, chronic infusion of Ang II increases transport-related oxygen consumption, an
indicator of NaCl reabsorption by the THAL54.

Altogether, these data indicate that

acutely and chronically Ang II stimulates ion transport by the THAL. However, whether
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this is due to direct effects on the transporters or whether Ang II impairs the ability of the
THAL to properly produce and respond to natriuretic mediators is not known.
In contrast to Ang II, NO is an endogenous vasodilator and natriuretic factor55-59.
In the renal vasculature NO induces vasodilatation, increases glomerular filtration rate
and elevates renal blood flow60-62 . In the nephrons, NO inhibits NaCl reabsorption by
proximal tubules63,64, THAL

65-67

and collecting ducts68.

The importance of

endogenously produced NO in maintaining normal blood pressure has been
demonstrated by blockade of renal NO synthases (NOS) using low doses of a NOS
inhibitor which induced Na retention and salt-sensitive hypertension69. In addition, it has
been shown that in Dahl salt-sensitive hypertensive rats, renal medullary NO levels and
actions in response to physiological stimuli are impaired70 and oral or intramedullary
administration of L-arginine (NOS substrate), increases natriuresis and decreases blood
pressure71-73.

Therefore, Ang II-induced hypertension could also increase Na

reabsorption by reducing NO production or impairing NO actions in the kidney.
However, findings in this model have been less conclusive and increases in NO
production have been found in the renal cortex74,75.
NO is produced by three NOS isoforms: NOS1 or neuronal, NOS2 or inducible
and NOS3 or endothelial. The THAL expresses all 3 NOS isoforms76; however, stimuli
shown to inhibit THAL NaCl transport such as endothelin-1 (ET-1), L-arginine and
clonidine mediate their effects via NOS3-mediated NO production77-79.

These data

indicate that NOS3 is the main source of NO responsible for the inhibition of NaCl
transport by the THAL.
Chronic increases in Ang II could decrease NO production by the THAL by
reducing NOS3 expression and NOS3 phosphorylation at stimulatory sites.

In
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endothelial cells, chronic exposure to NO reduces NOS3 expression and activity in a
negative-feedback fashion80,81. Since our lab has shown that acutely, Ang II enhances
NO production by the THAL82 it is possible that the same negative feedback is present
in THALs.

However, whether chronic elevations in Ang II reduce THAL NOS3

expression via NO is not known.
NO inhibits THAL NaCl reabsorption and NKCC2 activity by increasing cGMP67.
However, cGMP levels are also subject to degradation by phosphodiesterases (PDE)
like PDE583. PDE5 limits NO actions in smooth muscle cells by reducing cGMP levels
84,85

whereas Ang II increases PDE5 expression and activity86. Interestingly, in Dahl

salt-sensitive hypertensive rats, NO-induced decreases in THAL NaCl reabsorption are
impaired whereas cGMP production is not affected21, suggesting that enhanced cGMP
degradation could be present in hypertension. However, whether PDE5 is expressed in
the THAL and whether enhanced PDE5 blunts NO-induced inhibition of NKCC2 activity
in Ang II hypertension are not known.

1. d. Project Aims
We hypothesized that THAL NO production and inhibition of NKCC2 activity are
impaired in Ang II-induced hypertension.
In order to test our hypothesis we divided our work into three aims:
Aim I hypothesis: NO production in response to physiological stimuli is
impaired in THALs from Ang II-induced hypertensive rats. We measured NO production
in response to physiological stimuli as well as NOS3 expression and NOS3
phosphorylation in THALs from vehicle- and Ang II-treated rats.
Aim II hypothesis: Ang II decreases NOS3 expression via NO in THAL primary
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cultures. We measured NOS3 expression in response to chronic exposure to Ang II.
We delineated the signaling pathway by which Ang II reduces NOS3 expression in
THALs.
Aim III hypothesis: PDE5 blunts NO-induced increases in cGMP and inhibition
of NKCC2 activity in THALs from Ang II-hypertensive rats. We measured cGMP and
NKCC2 activity in response to NO in the presence and absence of the PDE5 inhibitor.
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CHAPTER 2
NITRIC OXIDE PRODUCTION IN RESPONSE TO PHYSIOLOGICAL STIMULI IS
IMPAIRED IN THICK ASCENDING LIMBS FROM ANGIOTENSIN IIHYPERTENSIVE RATS
2. a. Introduction
In the THAL, physiological stimuli such as ET-177,87 and L-arginine65,78 inhibit
NaCl reabsorption via NO produced by NOS3. The ability of the THAL to produce NO is
essential for those stimuli to inhibit NaCl transport, since such a response is absent in
THALs from NOS3 KO mice.

We have shown that in THALs decreases in NO

production in response to physiological stimuli are correlated with decreases in NOS3
expression88.

Therefore, studying THAL NOS3 expression in pathological states is

important to understand the mechanism by which NO production is impaired.
In the THAL increases in NO production in response to most physiological stimuli
are mediated by phosphatidyl inositol 3,4,5 tri-phosphate (PIP3) via activation of
phosphatidyl inositol 3 kinase (PI3K)77,82,89,90.

Increases in PIP3 enhance NOS3

phosphorylation at serine 1177 elevating NO production whereas blockade of PI3K
prevents stimuli-induced NO production. These data indicate that phosphorylation of
serine 1177 is an important event in the activation of NOS3 and that defects in this
process could lead to impaired NO production.
Our lab has shown that in Ang II-induced hypertension THAL transport is
enhanced54 suggesting that production of inhibitory molecules such as NO could be
decreased. Furthermore, cytokines that are increased in response to Ang II reduce
NOS3 expression by the THAL88. Therefore, we hypothesized that in Ang II-induced
hypertension THAL NO production in response to physiological stimuli is impaired and
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this correlates with reduced NOS3 expression and decreased phosphorylation at serine
1177.
2. b. Materials and Methods
Drugs: Unless otherwise stated, reagents and drugs were purchased from
Sigma (St. Luis, MO).
Ang II-induced hypertension: All protocols involving animals were approved
by the Institutional Animal Care and Use Committee (IACUC) of Henry Ford Hospital
and Wayne State University. Male Sprague Dawley rats weighing 90-120 g were fed
standard chow (0.4% Na) and infused with either vehicle (0.01 N acetic acid) or Ang II
at 200 ng/Kg/min via osmotic minipumps (Durect; model 1007D ) for 5 days (minipump
implantation was performed under isofluorane 1.5% in oxygen 0.5 L/min). Mean arterial
blood pressure was measured via the femoral artery at day 5 after treatment in
anesthetized rats (ketamine 90 mg/Kg, xylazine 10 mg/kg).
THAL suspensions: Suspensions were performed as we have done before
50,88,91

. Briefly, the abdominal cavity was opened, and the kidneys flushed with 40 mL

ice-cold 0.1% collagenase (Sigma; St. Louis, MO) containing 100 U heparin in
physiological saline via retrograde perfusion of the aorta. Kidneys were removed and
coronal slices cut. The inner stripe of the outer medulla was minced and digested in
0.1% collagenase at 37°C for 30 min. During each 5 min period, the tissue was gently
agitated and gassed with 100% oxygen. Tissue was centrifuged at 60 x g for 2 min; the
pellet was re-suspended in cold physiological saline and stirred on ice for 30 min. The
suspension was filtered through a 250 µm nylon mesh and centrifuged at 60 x g for 2
min. The pellet was washed and centrifuged again.
Western blot: Protein expression levels were measured using a modification of
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our previous technique88,91. Tubules were lysed in 500 µL of a solution containing 20
mmol/L HEPES (pH 7.5), 2 mmol/L EDTA, 0.3 mol/L sucrose, 1.0% Igepal CA-630,
0.1% sodium dodecyl sulfate, 5 µg/mL antipain, 10 µg/mL aprotinin, 5 µg/mL leupeptin,
4 mmol/L benzamidine, 5 µg/mL chymostatin, 5 µg/mL pepstatin A, and 0.116 mol/L pfblock (Sigma; St Louis, MO).

Debris was removed by centrifugation for 5 min at

5,600xg. Protein concentration was determined by a colorimetric assay (Coomassie
Plus protein assay, Pierce, Rockford, IL).
Equal amounts of protein from freshly prepared protein lysates from THAL
suspensions were loaded per lane. THAL proteins from one vehicle-treated rat and one
Ang II-treated rat were loaded per gel, so every gel had its own control.
NOS3: proteins were loaded in a 6 % SDS-polyacrylamide gel, separated by
electrophoresis, and transferred to a PVDF membrane (Millipore, Bedford, MA). The
membrane was incubated in blocking buffer containing 20 mmol/L Tris, 137 mmol/L
NaCl, 0.1% Tween 20 (TBS-T) and 5% nonfat dry milk for 60 min and then with a
1:1,000 dilution of an NOS3-specific monoclonal antibody (BD Transduction
Laboratories, San Diego, CA) in blocking buffer for one hour at room temperature. The
membrane was washed with TBS-T and incubated for 2 hours with a 1:1,000 dilution a
secondary antibody against mouse IgG conjugated to horseradish peroxidase
(Amersham Pharmacia Biotech, Arlington Heights, IL). Membranes were stripped and
reprobed for β-tubulin and optical density values of NOS3 were corrected by β-tubulin.
Control experiments for NOS3 Western blot running and transferring method was
performed when the technique was optimized. We found that the extreme lanes had
lower transference efficiency and that the change in optical density in the 4 central lanes
when the same sample was loaded was 0 ± 6 % vs lane #5 (n=3)88. Therefore, for all
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experiments we only used the central lanes for the experimental samples whereas the
remaining lanes were only loaded to ensure even running and transference.
NOS3 pS1177: When phosphorylation of NOS3 at serine 1177 was measured
(pS1177 NOS3) THAL suspensions were resuspended in 1 mL. Two aliquots of 300 µL
were incubated at 37ºC for 10 min, oxygenating every 5 min. THALs were then treated
with vehicle (2.5 µmol/L neomycin neosulfate carrier) or 2.5 µmol/L phosphatidylinositol
3,4,5-triphosphate (PIP3 stock was dissolved in perfusion solution containing Neomycin
Neosulfate 1:1 as a carrier, Echelon Biosciences, Salt Lake City, UT) for 8 minutes
oxygenating every 4 min. Suspensions were rapidly cooled by adding an equal volume
of cold perfusion solution containing 1:50 phosphatase inhibitors (cocktail set II EMD
biochemical), spun at 100xg for 2 min and lysed in lysis buffer containing 1:100
phosphatase inhibitors. Western blot for NOS3 pS1177 method was similar to NOS3 but
we used 1:2000 primary antibody (BD transduction)

92

and 1:2000 secondary antibody

against mouse IgG. Membranes were stripped and reprobed for NOS3 and optical
density values for pS1177 were corrected by NOS3.
ETB receptor: Proteins were loaded in 4% stacking- 9% running gels.
Membranes were then incubated for 1 hour with blocking buffer at room temperature,
followed for 1 hour incubation with a 1:1,250 dilution of anti-ETB antibody (AER002
Alomone) in blocking buffer, washed 8 times (2 quick, 1x 15 min and 5 x 5’) with TBS-T.
The membrane was then incubated with a 1:1,000 dilution of secondary antibody
against rabbit IgG conjugated to horseradish peroxidase (Amersham Pharmacia
Biotech, Arlington Heights, IL) and washed 10 times (2 quick, 1x 15 min and 7x 5 min).
As a control, the primary antibody was pre-incubated with a neutralizing peptide at a
peptide/antibody ratio= 1 (Alomone) followed by incubation with a secondary antibody
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under the above conditions. The band corresponding to ETB receptor was absent in the
pre-adsorption control experiment.

Membranes were stripped and re-probed for β-

tubulin and optical densities for ETB receptor were corrected by β-tubulin.
β-tubulin: Membranes were incubated with stripping buffer (glycine 0.2 mol/L
pH 2.8) for 30 min and then washed 4 times with TBS-T.

Membranes were then

incubated for 1 hour with blocking buffer at room temperature, followed for 1 hour
incubation with a 1:10,000 dilution of anti β-tubulin antibody (Abcam, Cambridge, MA) in
blocking buffer, washed 5 times with TBS-T and then incubated with a 1:5,000 dilution
of a secondary antibody against rabbit IgG conjugated to horseradish peroxidase
(Amersham Pharmacia Biotech, Arlington Heights, IL).
Protein detection and densitometry: The signal was detected by exposure
to Fuji Super RX film, which was scanned (EPSON expression 1680 scanner), and
densitometry was performed with a custom program. The exposure times for the film
were standardized to get bands of mean optical density between 0.40 and 1.00
Measurement

of

NO

production:

NO production was measured by

fluorescence microscopy in isolated THALs as we have done before77,82.

In brief,

tubules were isolated and transferred to a temperature-regulated chamber (37ºC) and
held by two glass pipettes in the absence of flow. The bath was started at 0.5 mL/min
and contained 100 µmol/L L-arginine, the substrate for NOS. At this concentration in
the absence of flow L-arginine does not stimulate but supports stimulus-induced NO
production90. Tubules were loaded with the NO-selective fluorescent dye 4-Amino-5Methylamino-2',7'-Difluorofluorescein Diacetate (DAF2-FM DA, 4 µmol/L; Molecular
Probes, Grand Island, NY) for 20 min, followed by a 20-min wash.

Tubules were

imaged using a 40x oil immersion objective, and the dye was excited with a xenon lamp
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using a 488 nm band pass excitation filter. The fluorescence emitted by NO-bound dye
(>500 nm) was measured using Metafluor software (Molecular devices). Measurements
were recorded once every 30 sec for a 10-min control period. ET-1 (1 nmol/L prepared
in 0.005% acetic acid; Bachem, Torrance, CA), vehicle (0.005% acetic acid), 2.5 µmol/L
PIP3 (stock dissolved in perfusion solution containing 1:1 neomycin neosulfate as a
carrier, Echelon Biosciences, Salt Lake City, UT) or perfusion solution was then added
to the bath.

Fluorescence was measured once every 30 sec during a 10-min

experimental period. DAF-FM-DA binds NO in an irreversible manner and therefore NO
production was measured as the slope of fluorescence over time.

Since in the

presence of 100 µmol/L L-arginine but not stimuli, NO production is negligible93, we took
the slope of fluorescence over time (Fluorescence units FU/min) obtained during the
last 5 min of the basal period as an internal control for dye loading and subtracted it
from the highest 5 min slope observed during the experimental period. Of note, the
slope of fluorescence over time during the basal period was not different between
control and hypertensive rats (for the ET-1 experiments; vehicle: 0.21 ± 0.05 vs Ang: II
0.21 ± 0.06 AU/min; for the PIP3 experiments; vehicle: 0.31 ± 0.08 vs Ang II: 0.27 ±
0.10 AU/min).
Statistical analysis: Results are expressed as mean ± SE.

Data were

analyzed by the Biostatistics and Research Epidemiology Department of Henry Ford
Hospital. Paired t-tests and 2-sample Wilcoxon tests were used as appropriate. When
multiple pair-wise comparisons were made, Hochberg’s procedure for multiple tests of
significance was applied94.
2. c. Results
First, we measured blood pressure and found that rats infused with 200
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ng/Kg/min Ang II for 5 days had a mean arterial blood pressure about 20 mm Hg higher
compared with vehicle-treated rats (vehicle: 96 ± 4 mm Hg, n = 5 vs Ang II: 120 ± 8 mm
Hg, n = 4; p < 0.02) indicating that this treatment induces a small but significant
increase in blood pressure.
Next, we studied whether Ang II-induced hypertension affects NOS3 expression
in the THAL. We found that in THALs from Ang II hypertensive rats NOS3 expression
was decreased by 40 ± 12% (n = 6, p < 0.007, Figure 2).

NOS3/β-tubulin expression
(% of vehicle-treated)

NOS3
tubulin

120
100

Figure 2. NOS3 protein expression
in THALs from vehicle- and Ang IItreated rats. Top: representative
Western blot for NOS3. Bottom:
cumulative data (n = 6; p < 0.007).
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Our lab has shown that ET-1 increases NO via NOS3 in the THAL77; therefore,
we tested whether reduced NOS3 expression resulted in impaired ET-1-induced NO
production in Ang II-hypertensive rats. We found that NO production in response to 1
nmol/L ET-1 was increased in THALs from vehicle-treated rats (0.167 ± 0.021 AU/min,
n=8) but not in THALs from Ang II-treated rats (-0.012 ± 0.057 AU/min, n=7 p<0.01
Figure 3). These data suggest that reduced NOS3 expression in THALs from Ang IIhypertensive rats correlates with blunted ET-1-induced NO production.

ET-1-induced NO production
(Fluorescence Units/min)
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Figure 3. Effect of ET-1 on NO
production by isolated THALs from
vehicle- and Ang II-treated rats.
Intracellular NO production in response
to 1 nmol/L ET-1 was measured by
fluorescence microscopy in isolated
THALs using DAF-FM-DA (vehicle n=
8; Ang II n= 7; p < 0.01).
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p<0.01
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In the THAL ET-1 increases NO production by activating ETB receptors87,95.
However, it has been shown that ETB receptor levels are decreased in renal inner
medullas from Ang II-hypertensive rats46. To rule out the possibility that impaired NO
production in response to ET-1 was due to reduced ETB receptors, we measured ETB
expression in THALs by Western blot. Contrary to what has been reported in the inner
medulla, ETB receptors were not decreased in THALs from Ang II-hypertensive rats (∆ =
0 ± 15%; n = 6, Figure 4). These data suggest that reduced ETB receptors are not the
likely the cause of impaired ET-1-induced NO production.
A
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Figure 4. ETB receptor expression in THALs from vehicle- and Ang II-treated rats. A)
control Western blot for ETB showing disappearance of band by pre-incubation of the
antibody with a blocking peptide; B) representative Western blot for ETB from THALs
from THALs from vehicle- and Ang II-treated rats C) cumulative data (n = 6; NS).
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In the THAL, activation of NOS3 by hormones and autacoids is mediated by PI3K
and its product PIP377,89,90. To test whether impaired ET-1-induced NO production was
due to a defect downstream or upstream from PI3K, we measured NO in response to
PIP3. PIP3-induced increases in NO were blunted in THALs from Ang II-treated rats
(vehicle: 0.128 ± 0.036 vs Ang II: -0.065 ± 0.054 AU/min n = 4; p < 0.03 Figure 5).
These data indicate that the defect in NO production in THALs from Ang II hypertensive
rats is downstream from PIP3 and therefore likely to be present in response to all the

PIP3-induced NO production
(Fluorescence Units/min)

stimuli that utilize this pathway.
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Figure 5. Effect of PIP3 on NO
production by isolated THALs from
vehicle- and Ang II-treated rats.
Intracellular NO production in response
to 2.5 µmol/L PIP3 was measured by
fluorescence microscopy in isolated
THALs using DAF-FM-DA (vehicle n= 4;
p < 0.03).
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Finally, we tested whether phosphorylation of NOS3 at the stimulatory site serine
1177 in response to PIP3 was also impaired in THALs from Ang II hypertensive rats.
Treatment of THALs from vehicle-treated rats with 2.5 µmol/L PIP3 increased pS1177
NOS3/NOS3 by 18 ± 4 % (Figure 6A, n= 5 p< 0.015). However, in THALs from Ang IIhypertensive rats PIP3 was not able to increase phosphorylation at pS1177 (Figure 6B,

∆= - 1 ± 18 %, n= 5). These data indicate that in THALs from Ang II-hypertensive rats
stimuli-induced NO production is impaired and this is likely due in part to impaired
NOS3 phosphorylation at serine 1177.
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Figure 6. Effect of PIP3 on NOS3 phosphorylation. A) Effect of PIP3 on NOS3
phosphorylation at S1177 in THALs from vehicle-treated rats. Cumulative data showing
% change in pS1177 NOS3/total NOS3 in response to 2.5 µmol/L PIP3, n= 5. B) Effect
of PIP3 on NOS3 phosphorylation at S1177 in THALs from Ang II-treated rats.
Cumulative data showing % change in pS1177 NOS3/total NOS3 in response to 2.5
µmol/L PIP3, n= 5.

2. d. Discussion
We hypothesized that THAL NOS3 expression is decreased and that NO
production in response to physiological stimuli is impaired in Ang II-induced
hypertension.

We found that in THALs from Ang II-hypertensive rats: 1) NOS3

expression was decreased; 2) ET-1- and PIP3-induced NO production were blunted; 3)
ETB receptor expression was not changed and 4) PIP3-induced phosphorylation of NOS
3 at serine 1177 was increased in THALs from vehicle- but not from Ang II-treated rats.
Altogether these data indicate that in Ang II-induced hypertension THAL NO production
in response to physiological stimuli is decreased and this is likely due to reduced NOS3
expression and impaired phosphorylation at serine 1177 (Figure 7).
Ang II is a pleiotropic hormone that affects many systems, including the
kidneys96, blood vessels30, heart97 and nervous system98. Chronically infusing even low
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Figure 7. Summary of results from Chapter
2. ET-1 and PIP3 increase NO production
by the THAL. Ang II-hypertension impairs
this response by reducing THAL NOS3
expression
and
PIP3-induced NOS3
phosphorylation at serine 1177.
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doses of Ang II can shift the pressure natriuresis curve to the right99,100. Physiologically
this is seen as salt-sensitive hypertension24,26,27,101,102. A large range of Ang II dosages
has been used to induce hypertension in rats, from 5 ng/kg/min103 to 600 ng/kg/min104;
however, at doses exceeding 400 ng/kg/min Ang II-induced hypertension is no longer
salt-sensitive105. We infused Ang II at a dose of 200 ng/kg/min because at this dose
Ang II increases blood pressure in a salt-sensitive manner, indicative of impaired renal
function105.
Most of the studies using Ang II treatment as a way to increase blood pressure,
have infused Ang II for 7 days or more24,39,106,107. We have chosen 5 days of treatment
for several reasons. First, we were interested in studying changes that occur in the
THAL in rats exposed to modest yet significant increases in blood pressure. In our
study Ang II-hypertensive rats had a mean arterial blood pressure that was about 20
mmHg higher than control rats. Second, we wanted to study how Ang II impairs the
ability of physiological stimuli to increase NO production and to inhibit Na reabsorption
by the THAL.

It has been shown that during the first days of Ang II infusion, Na

reabsorption by the kidney is enhanced24; however, with the increase in blood pressure,
this effect is overcome and increased Na excretion is observed100.

Furthermore,

Crowley et al. showed that cumulative Na excretion measured during the first 5 days of
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Ang II infusion was significantly higher in mice lacking AT1 receptors in the kidney
compared to WT or AT1 KO mice transplanted with WT kidneys, suggesting that Ang IIinduced increases in renal Na reabsorption can be observed during the first 5 days of
Ang II infusion and is dependent on effects in the kidney24.

Finally, we wanted to

investigate the causes rather than the consequences of hypertension and exposure to
high Ang II levels and high blood pressure for a long period induces renal damage108,109.
Therefore, we chose 5 days of Ang II treatment to study NO production in response to
physiological stimuli as a good compromise between the effect of Ang II in blood
pressure, renal Na reabsorption and renal damage.
The THAL expresses all three NOS isoforms: NOS1, 2 and 376. However, unlike
the collecting duct, where ET-1 activates NOS1 and NOS3110-112, in the THAL the NOS
isoform that mediates ET-1-induced NO production is NOS377. NOS3 is the source of
NO in response to many stimuli including L-arginine78, ATP89 and clonidine79. Since
NOS3 is responsible for stimuli-induced NO production in the THAL, we focused on this
isoform. We found that Ang II-induced hypertension decreased NOS3 expression by
the THAL.
Although most of the reports in Dahl salt-sensitive hypertensive rats have shown
a deficiency in NO production or effects21,22,71,113,114 the results found in Ang IIhypertension are controversial. It has been shown that infusion of Ang II for 7 days at
600 ng/kg/min104; or for 14 days at 280 ng/kg/min did not alter NOS3 expression75. In
contrast NOS3 expression in the outer medulla was reduced in a model of 2 kidney-1
clip hypertension where Ang II levels are increased104.

Finally, NO-dependent

medullary renal blood flow was reduced in Ang II-hypertensive rats, suggesting that NO
levels were reduced in the medulla of Ang II-hypertensive rats74. Our results show that
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chronic infusion of Ang II reduces NOS3 expression and NO production in the THAL.
The reason for the difference between our results and those shown in the whole outer
medulla is likely to be the fact that the presence of different type of cells (thin
descending limbs, S3 proximal tubules, vasa recta, interstitial cells) may have masked
the change observed in THALs.

It is also possible that higher increases in blood

pressure or longer exposure to hypertension could initiate compensatory mechanisms
that increase NOS3.

To our knowledge this is the first time that reduced NOS3

expression and NO production by the THAL have been observed in Ang II-induced
hypertension.
We have previously shown that ET-1 increases NO production by stimulating
NOS3 in the THAL77.

The NO thus formed inhibits NKCC2 and reduces NaCl

reabsorption in this nephron segment77,87. Stimulation of NO production by ET-1 is not
unique to the THAL. Other cell types like collecting duct cells as well as endothelial
cells increase NO production in response to ET-1110-112. In those cells concentrations of
0.1 nmol/L to 50 nmol/L ET-1 have been used. We used 1 nmol/L ET-1 based on our
previous experience showing that at this concentration ET-1 stimulates NO production
and inhibits NKCC2 activity and NaCl reabsorption in THALs87,95.
Changes in ETB receptor density or expression in the kidney have been shown in
animals fed high salt115, salt-sensitive spontaneously hypertensive rats116, and animals
treated with Ang II46,117,118.

In proximal tubules Ang II increases ETB density by

activating AT1 receptors119. In contrast, in inner medullary collecting ducts ETB density
was found to be reduced in heart failure but could be restored to normal by suppressing
Ang II production117.

Kittikulsuth et al46 recently showed that in Ang II-induced

hypertension, ETB receptor agonist-induced natriuresis was blunted and this correlated
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with reduced ETB receptors in the inner medulla. To test whether ETB receptor levels
were reduced in THALs from Ang II-hypertensive rats we measured ETB receptor
expression. We found that unlike the inner medulla, ETB receptor expression was not
reduced in the THAL. These data suggest that fewer ETB receptors were not likely to
be the cause of the impaired ET-1 response in THALs from hypertensive rats.
Most of the renal natriuretic effects of ET-1 have been attributed to activation of
ETB receptors120. ETA receptors are mainly found in vascular smooth muscle cells and
collecting duct cells120. To our knowledge neither ETA receptor expression nor ETA
receptor function has been found in the THAL87,95,121.

Moreover, inhibition of ETA

receptors did not affect basal NaCl reabsorption, ET-1-induced inhibition of NaCl
reabsorption87 or ET-1-induced increases in NOS3 expression by the THAL95. Although
we cannot rule out the possibility that Ang II-hypertension induces ETA receptor
expression by the THAL it is not likely to be the cause of impaired ET-1-induced NO
production in Ang II-hypertension since the response to PIP3, an ETB downstream
mediator, is also blunted.
Most of the stimuli that increase NO production by the THAL, like ET-177, ATP89,
flow90, Ang II type 2 (AT2) receptor agonists82 and alpha 2 adrenergic agonists79, do so
by activating PI3K. To study whether the defect observed in Ang II-hypertension was
unique to ET-1 or a general phenomenon due to blunted signaling downstream from
PI3K, we bypassed the ETB receptors and stimulated cells with PIP3, the product of
PI3K. As expected, PIP3-induced NO production was also blunted in Ang IIhypertensive rats. Altogether, these data suggest that stimuli-induced NO production is
impaired in THALs. These data also provides a second line of evidence that reduced
ETB receptor availability is not likely to be the cause of impaired NO production by the
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THAL.
NOS3 has at least three putative phosphorylation sites that can alter its activity,
but serine 1177 is the key site for stimulation of activity. Phosphorylation at this site has
been shown to increase NOS3 activity by enhancing electron flow through the
reductase domain and increases NO
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whereas mutations that prevent this site from

being phosphorylated block stimuli-induced NO production
THALs stimuli including
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. We have shown that in

ET-1 and flow activate PI3K and increase NOS3

phosphorylation at serine 1177 thus augmenting NO production

77,90

. Multiple kinases

like protein kinase B or Akt, protein kinase A, AMP-dependent protein kinase and
calmodulin-dependent protein kinase phosphorylate NOS3 at serine 1177

124,125

.

Among them the most studied is Akt. Akt is activated in response to increases in PIP3,
the product of PI3K, and in THALs mediates the stimulatory effects of ET-177,95, ATP89
and AT2 receptor agonists on NOS382. In addition, phosphorylation at this site can be
reduced by protein phosphatase 2 (PP2)126,127 and Ang II increases PP2A activity in
cardiomyocytes128. However, whether Ang II increases PP2 activity in the THAL is not
known. We found that phosphorylation of NOS3 at serine 1177 was not increased in
response to PIP3 in THALs from Ang II-hypertensive rats, suggesting either reduced Akt
activation or enhanced phosphatase activity.
In conclusion, we found that THAL NOS3 expression is decreased and that
physiological stimuli-induced NO production and NOS3 phosphorylation at serine 1177
are impaired in Ang II-induced hypertension.
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CHAPTER 3
ANGIOTENSIN II DECREASES NOS3 EXPRESSION IN THICK ASCENDING LIMB
PRIMARY CULTURES
3. a. Introduction
We have found that Ang II-induced hypertension reduces NOS3 expression in
the THAL and impairs the ability of physiological stimuli to increase NO production
(Chapter 2).

However, whether this is a direct effect of Ang II in the THAL or is

secondary to in vivo changes observed in Ang II-hypertension (namely increases in
blood pressure, elevated lymphocyte infiltration, increases in sympathetic nerve activity)
is not clear.
In endothelial cells, increased NO reduces NOS3 expression80 and activity81 via
protein kinase G (PKG) in a negative-feedback fashion. Interestingly acute treatments
with Ang II enhanced NO production in the kidney in general129,130 and in the THAL in
particular82,131-133. However, whether the same negative feedback is present in THALs
in response to Ang II is not known. Therefore, we hypothesized that Ang II decreases
NOS3 expression in THALs via NO. In this aim we used THAL primary cultures to test
the direct effect of Ang II on NOS3 expression and to avoid the confounding effects that
increases in blood pressure or chronic Ang II infusion would have on NOS3 expression.

3. b. Materials and Methods
Primary cultures of THALs: All protocols involving animals were approved by
the Institutional Animal Care and Use Committee (IACUC) of Henry Ford Hospital and
Wayne State University. The composition of physiological saline used was (in mmol/L)
130 NaCl, 2.5 NaH2PO4, 4 KCl, 1.2 MgSO4, 6 D/L-alanine, 1 trisodium citrate, 5.5
glucose, 2 calcium dilactate, and 10 HEPES. The solution was adjusted to 320 ± 3
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mosmol/kgH2O with mannitol and was pH 7.4 at room temperature. Male SpragueDawley rats (Charles River Breeding Laboratories, Wilmington, MA) were maintained on
a diet containing 0.4 % sodium and 1% potassium (Teklad Rodent Diet #8640, HarlandTeklad, Madison, WI). Rats weighing 200–250 g were anesthetized with ketamine and
xylazine (100 and 20 mg/kg body wt ip, respectively).

THAL suspensions were

generated as described in Chapter 2. THALs obtained from two kidneys (one rat) were
re-suspended in 1 mL DMEM/F-12 (Invitrogen; Eugene, Oregon) supplemented with 5%
heat-inactivated fetal bovine serum (HyClone; Logan, UT), 100 U/mL penicillin, 100
µg/mL streptomycin (HyClone) and 20 ng/mL EGF (Invitrogen; Eugene, Oregon)95.
Cells were plated on collagen-coated inserts (0.4-µm pore size, 4.7-cm2 area, Corning
Costar, Cambridge, MA) at a concentration of 80 µg protein/insert and placed in an
incubator at 37°C and 95% O 2, 5% CO2. The use of these inserts promotes cell
polarization and allows THALs to be treated on the basolateral and apical side.
Previously our lab showed that 92 % of cells in primary cultures were THALs as
evidenced by positive Tamm-Horsfall immune-staining95. After 40 hrs of seeding, cells
were treated with either vehicle (DMEM/F-12 medium) or Ang II 0.1, 1, 10 or 100 nmol/L
(Calbiochem; EMD, La Jolla, CA) for 24 hrs. In experiments involving NG-nitro-Larginine methyl ester hydrochloride (L-NAME, a NOS inhibitor), tempol (a superoxide
dismutase mimetic; Sigma St. Louis, MO) or carboxy-PTIO (c-PTIO, a NO scavenger;
Cayman Chemical Ann Arbor, Michigan), cells were preincubated for 1 hr with the
reagent and then the medium was changed to one containing 100 nmol/L Ang II plus; 1)
L-NAME, 2) tempol, 3) c-PTIO or 4) L-NAME + spermine NONOate (NO donor, Cayman
Chemical Ann Arbor, Michigan) for 24 hrs. All treatments were added to the basolateral
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and apical sides, always included one vehicle (control) and one Ang II (positive control)
treatment and were done in the presence of 5% fetal bovine serum.

Western blot: was performed as detailed in Chapter 2.
Statistical analysis: Results are expressed as percentage of control ± standard
error. Data were analyzed by the Biostatistics and Research Epidemiology Department
from Henry Ford Hospital with an analysis of slope for concentration dependent
responses and paired t test. In some experiments ANOVA was used with post hoc
testing. When multiple pair-wise comparisons were done, a procedure for multiple tests
of significance was applied using Hochberg’s significance limits.94

3. c. Results
To study the effect of Ang II itself on NOS3 expression and distinguish it from in

vivo effects, we used THAL primary cultures. Treatment of THALs with 10 and 100
nmol/L Ang II for 24 hrs decreased NOS3 expression by 23 ± 9% (n = 6, p<0.05 vs.
control) and 50 ± 5% (n = 7, p<0.001 vs control) respectively (Figure 8). Lower Ang II
concentrations (0.1 and 1 nmol/L) did not significantly affect NOS3 expression (∆= -7 ±
10 and ∆= -14 ± 22 vs. control, respectively).
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Figure 8. Effect of Ang II in NOS3
expression in THALs. THAL primary
cultures were incubated with 10 and 100
nmol/L Ang II for 24 hrs and NOS3
expression was assessed by Western
blot. Top: Representative Western blot.
Bottom: Cumulative data from 6 and 7
independent measurements for 10 and
100nmol/L, *=p<0.05, **=p<0.001 vs 0
nmol/L respectively.
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Acutely, Ang II activates NOS in THALs82,131 and NO negatively regulates NOS3
expression in endothelial cells80. Therefore, we next studied whether Ang II decreases
NOS3 expression via a NO-mediated negative feedback mechanism. First we tested
whether NOS activation was required for Ang II-induced reduction of NOS3 expression.
In these experiments, 100 nmol/L Ang II alone reduced NOS3 expression by 27 ± 5%
(n=5). In contrast, in the presence of L-NAME, a NOS inhibitor, Ang II had no significant
effect on NOS3 expression (∆= -5 ± 8% vs control, n=5; p<0.007 vs Ang II alone; Figure
9). L-NAME alone had no effect on basal NOS3 expression (∆= -2 ± 8% vs control,
n=5). These data indicate that NOS activity is required for Ang II to reduce NOS3
expression.
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Figure 9. Effect of NOS inhibition on Ang IIinduced decrease in NOS3 expression in
THALs. Top: Representative Western blot.
Bottom: Cumulative data from 5 independent
measurements; *=p<0.007 vs L-NAME+ Ang
II.
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Figure 10. Effect of NO scavenging on Ang
II-induced decrease in NOS3 expression in
THALs. Top: Representative Western blot.
Bottom:
Cumulative
data
from
6
independent measurements, no significant
difference.
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Next we tested whether NO per se was involved in Ang II-induced inhibition of
NOS3 expression by using c-PTIO, a NO scavenger134. In these experiments Ang II
alone reduced NOS3 expression by 33 ± 4% (n = 6). In contrast, in the presence of 10
µmol/L c-PTIO, Ang II had no significant effect on NOS3 expression (∆= -1 ± 8%, n = 6

vs c-PTIO alone; Figure 10). c-PTIO alone did not significantly change NOS3
expression (n=6). Taken together, these data indicate that NO is required for Ang II to
reduce NOS3 expression.

Figure 11. Effect of NOS inhibition and
addition of exogenous NO on Ang IIinduced decrease in NOS3 expression in
THALs. Top: Representative Western
blot. Bottom: Cumulative data from 7
independent measurements; *=p<0.013
vs L-NAME + spermine NONOate.
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In order to evaluate whether the effect of Ang II on NOS3 expression was only
due to NO, we tested the effect of a NO donor on NOS3 expression. To maximize the
effect we inhibited endogenous NO production with L-NAME. However, in the presence
of L-NAME, addition of the NO donor spermine NONOate (1 µmol/L) did not have any
effect on NOS3 expression (∆= 2 ± 10 %, n = 7). Interestingly, when cells were treated
with Ang II in the presence of L-NAME plus the NO donor spermine NONOate (1
µmol/L), NOS3 expression decreased by 22 ± 6% (n=7; p<0.013 vs L-NAME + NO
donor; Figure 11) an effect similar to that observed when Ang II alone was added (∆= 28 ± 7%, n = 7). These data indicate that NO is necessary but not sufficient to reduce
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NOS3 expression in THALs and that simultaneous activation of another mechanism by
Ang II is necessary for NO to reduce NOS3 expression.
Ang II not only increases THAL NO but also superoxide production50,132,133 which
reacts with NO to produce the highly oxidant molecule peroxynitrite. Consequently, we
studied whether superoxide was also involved in Ang II-induced reductions in NOS3
expression. Ang II alone reduced NOS3 expression by 29 ± 3% (n=6); however, in the
presence of tempol, a superoxide scavenger135, Ang II failed to decrease NOS3
expression (∆= -3 ± 7%, n = 6; p<0.015 vs Ang II) and tempol alone did not affect NOS3
expression (∆= 6 ± 12%; n = 6; Figure 12).
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Figure
12.
Effect
of
superoxide
dismutation on Ang II-induced decrease in
NOS3 expression in THALs. Top:
Representative Western blot. Bottom:
Cumulative data from 6 independent
measurements; *=p<0.015 vs tempol +
Ang II.
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The tempol results could be due to either a reduction in superoxide which is
required for Ang II to decrease NOS3; or the generation of hydrogen peroxide which
has been reported to enhance NOS3 expression in endothelial cells136. We reasoned
that if hydrogen peroxide was masking the effect of NO in NOS3 expression, then in the
presence of tempol Ang II should increase NOS3 expression when NOS is inhibited.
Thus, we incubated cells with or without Ang II in the presence and absence of both LNAME and tempol. Ang II alone reduced NOS3 expression by 40 ± 6%. In contrast, Ang
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II had no effect on NOS3 expression in the presence of L-NAME and tempol, (∆= 2 ±
7% vs L-NAME+ tempol). L-NAME and tempol did not affect basal NOS3 expression in
the absence of Ang II. Taken together, these data indicate that the ability of tempol to
block Ang II-induced inhibition of NOS3 expression is due to a reduction in superoxide
rather than an increase in hydrogen peroxide.

3. d. Discussion
We found that Ang II decreases NOS3 expression in THALs via NO and
superoxide and thus is likely mediated by peroxynitrite (Figure 13).
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Figure 13. Summary of results
from Chapter 3. Acutely, Ang II
increases NO via AT2 and
superoxide (O2-) via AT1 receptors.
Chronic exposure to Ang II results
in decreases in THAL NOS3
expression via both NO and
superoxide
suggesting
that
peroxynitrite mediates this effect.
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We used primary cultures of THALs to avoid confounding influences like those
occurring in response to changes in blood pressure137, renal blood flow138,
tubuloglomerular feedback139,140, transport in the proximal tubule141,142, nerve activity31
or inflammation143,144 caused by Ang II infusion may have on THAL NOS3 expression.
We found that treatment of THAL primary cultures with 10 and 100 nmol/L Ang II for 24
hrs decreased NOS3 expression in a concentration dependent manner. These data are
consistent with our previous finding that in vivo Ang II reduces NOS3 expression in the
THAL. These data also indicate that they are due to a direct effect of Ang II on NOS3
expression rather than secondary to in vivo changes induced by chronic Ang II infusion.
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In endothelial cells NO donors decrease NOS3 expression

80

and acutely, Ang II

increases NO production in the THAL by stimulating the Ang II type 2 (AT2)
receptor82,131. Thus, we next tested whether Ang II reduces NOS3 expression via an
increase in NO in THALs. We found that the effect of Ang II on NOS3 expression was
blocked by L-NAME indicating that NOS activity was necessary for Ang II to reduce
NOS3 expression. Then, we studied whether NO per se was involved by scavenging
NO with c-PTIO. C-PTIO blocked Ang II-induced decreases in NOS3 expression
indicating that NO is indeed required for Ang II to inhibit NOS3 expression in THALs.
One unexpected finding was that in the absence of Ang II, addition of the NO
donor spermine NONOate to the incubation medium in the presence of L-NAME did not
reduce NOS3 expression, indicating that the effect of Ang II was not solely due to NO
and that the simultaneous presence of another signaling molecule was necessary for
NO to reduce NOS3 expression. In addition to stimulating NO synthesis, Ang II
augments oxidative stress in the THAL by increasing superoxide production50,54,132,133;
and superoxide in turn, reacts with NO to form peroxynitrite. Thus, we investigated
whether superoxide dismutation prevented Ang II from decreasing NOS3 expression.
Tempol, a superoxide dismutase mimetic135, abolished the effect of Ang II on NOS3
expression. These data suggest that superoxide is required for the Ang II-induced
decreases in NOS3 expression.
Since superoxide dismutation results in increased hydrogen peroxide
hydrogen peroxide enhances NOS3 expression in endothelial cells

136

145

, and

, the ability of

tempol to block Ang II’s effect on NOS3 could also be explained by increased hydrogen
peroxide. To show that the effect of tempol was due to superoxide dismutation rather
than a parallel increase in NOS3 expression induced by hydrogen peroxide, we treated
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cells with both L-NAME and tempol.

If Ang II increased NOS3 expression in the

presence of L-NAME and tempol, this would mean that increased hydrogen peroxide is
responsible for the apparent blocking effect of tempol. On the other hand, if Ang II had
no effect on NOS3 expression in these experiments, it would indicate that superoxide is
required for the Ang II-induced reduction in NOS3 expression. Simultaneous treatment
of THAL cells with L-NAME, tempol and Ang II did not change NOS3 expression. Thus
we conclude that superoxide participates in Ang II-induced decreases in NOS3
expression.
Our results show that both NO and superoxide are required for Ang II to inhibit
NOS3 expression in THALs. Superoxide can react with NO to form peroxynitrite146
suggesting that peroxynitrite may mediate the actions of Ang II on NOS3. Ang II has
been shown to increase tyrosine nitration, a marker of peroxynitrite,147,148 in endothelial
cells149, proximal tubule150 and renal outer medulla tissue151.

In bovine aortic

endothelial cells, peroxynitrite decreases NOS3 expression152 whereas in diabetes an
inverse relationship between NOS3 expression and tyrosine nitration has been
delineated153. Moreover, it has been shown that treatment of endothelial cells with LDL
and oxidized LDL results in increased peroxynitrite production and decreased NOS3
expression154,155 and high glucose reduced NOS3 expression via peroxynitrite133,152,155.
Thus, peroxynitrite may mediate the effects of Ang II on THAL NOS3 expression.
The source of superoxide responsible for Ang II-induced decreases in THAL
NOS3 expression needs further study. However, the most likely sources are NADPH
oxidase and NOS itself. Ang II increases superoxide production via NADPH oxidase in
the THAL133. Additionally, Ang II induces NOS uncoupling149,156, thereby increasing
superoxide production. Thus, it is possible that NOS itself could become the source of
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both the NO and superoxide required for Ang II to inhibit NOS3 expression. Although
we showed that L-NAME blocks the effects of Ang II, and L-NAME could block both NO
and superoxide production by NOS156-158 addition of exogenous NO was sufficient to
revert the blockade of Ang II-induced decreases in NOS3 caused by L-NAME. Thus,
these data appear to rule out the possibility that uncoupled NOS is the source of
superoxide.

3. e. Copyright and permission notice
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CHAPTER 4
NO-MEDIATED INHIBITION OF NKCC2 ACTIVITY IS IMPAIRED IN THICK
ASCENDING LIMBS FROM ANGIOTENSIN II-HYPERTENSIVE RATS
4. a. Introduction
NO is an important mediator of natriuresis and vasodilatation.

In the THAL

endogenous as well as exogenous NO reduces NKCC2 activity66,77,159. We have found
that THAL NO levels in response to physiological stimuli are impaired in Ang II-induced
hypertension (Chapter 2). Similarly, reduced NO production has been shown in saltsensitive hypertension113,114 indicating that defects in this signaling mechanism could
mediate increases in Na reabsorption and blood pressure. In addition, our lab has
shown that NO-induced inhibition of THAL NaCl reabsorption is impaired in THALs from
Dahl salt-sensitive hypertensive rats21,159. However, whether the response to NO is also
impaired in THALs from Ang II-hypertensive rats is not known.
In the THAL NO inhibits NaCl reabsorption by activating soluble guanylate
cyclase and increasing cGMP, which reduces NKCC2 levels at the plasma
membrane67,160.

Disruption of NO or cGMP production impairs Na excretion and

increases blood pressure113,161. cGMP levels can be reduced by cyclic nucleotide PDEs
which degrade cGMP by breaking the phosphodiester bond83. One important PDE that
reduces NO-induced cGMP in smooth muscle cells is PDE584,85. However, whether
PDE5 regulates THAL cGMP levels in Ang II-hypertension is not known.
The role of PDE5 in hypertension has been addressed mainly in heart failure and
pulmonary hypertension, where PDE5 inhibition is being used as part of the antihypertensive therapy162-164. Thus most of the studies relating PDE5 and blood pressure
have been performed in the vasculature and the heart. However, there has been some
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indication of a role of PDE5 in Na reabsorption by the kidney165-167. Sasser et al. for
example, have shown that PDE5 inhibition increases Na excretion in pregnant versus
non-pregnant rats165. Interestingly, acute Ang II treatment increases PDE5 and reduces
cGMP levels in smooth muscle cells86 and Ang II-induced hypertension elevates PDE5
expression and activity in cardiomyocytes168 Therefore, we hypothesized that PDE5
blunts NO-induced increases in cGMP and inhibition of NKCC2 in THALs of Ang II
hypertensive rats.

4. b. Methods
Drugs: Unless otherwise stated, reagents and drugs were purchased from
Sigma (St. Louis, MO).

Ang II-induced hypertension: As described in Chapter 2.
Isolation and perfusion of rat THALs: THALs were isolated and perfused as
it has been done before in our lab77,159,169,170.

Once the rat was anesthetized, the

abdominal cavity was the kidney was bathed in ice-cold saline and removed. Coronal
slices were placed in oxygenated physiological saline containing (in mM) 130 NaCl, 2.5
NaH2PO4, 4 KCl, 1.2 MgSO4, 6 D/L-alanine, 1 trisodium citrate, 5.5 glucose, 2 calcium
dilactate, and 10 HEPES (pH 7.4). THALs were dissected from the outer medulla under
a stereomicroscope at 4°C and transferred to a temp erature-regulated chamber, where
they were perfused using a concentric glass pipette at 37 ± 1°C as described
previously77,159.

Measurement of NKCC2 activity: Tubules were perfused at 37°C in a
chamber on the stage of a Nikon Diaphot inverted microscope with a solution designed
to prevent Na-K-2Cl cotransporter activity, containing (in mmol/L) 0 Cl, 2.5 NaH2PO4,
1.2 MgSO4, 6 L-alanine, 1 Na3 citrate, 5.5 glucose, 2 Ca dilactate, 10 HEPES (pH 7.45
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with KOH) and 237 mannitol. Experiments where ET-1 was used were performed in the
presence of 100 µmol/L L-arginine; however, the others were performed in the absence
of this aminoacid to avoid endogenous production of NO. THAL cells were loaded by
bathing them for 20 min in physiological saline (composition see isolation and perfusion
of rat THALs) containing 2 µmol/L Na-sensitive fluorescent dye Sodium Green (Na
green Molecular Probes) for measurements of intracellular Na (Nai).

Loading was

followed by a 20 min wash with physiological saline. Na green was prepared daily. Na
green-loaded tubules were excited using a Xenon arc lamp filtered through two
KG1filters and a 488 band pass filter. Emitted fluorescence passed a 505 nm dichroic
mirror and then a 515 nm long-pass filter. A cool SNAP HQ2 camera (Photometrics)
was used to record the images which were stored and analyzed with a Metafluor
system. Images were acquired during 500 msec every 5 sec for a 12 min period. One
region covering the whole tubule was used to quantify fluorescence. Then, the luminal
solution was switched from 7.4 Na-0Cl-4.8K to 142 Na-134Cl-4K (both containing 100
µM 5-(N,N-dimethyl)amiloride hydrochloride to prevent Na/H exchanger activation). The
increase in Nai caused by the switch is due to activation of the Na-K-2Cl cotransporter66
and the initial rate of increase in fluorescence was used to calculate cotransport activity.
Then the luminal solution was switched back to 7.4 Na-0Cl-4.8K and the tested drug
was added to the bath. After 20 min the maneuver was repeated. To calculate NKCC2
activity we measured the slope of fluorescence units(FU) corrected by fluorescence at
time 0 (the time at which luminal solutions were switched) times 1000 (represented as
arbitrary units or AU) over time in seconds (sec) and we used the first five acquisitions
(first 20 seconds) to calculate this initial rate.
When tempol was used to scavenge superoxide, it was added to the bath during
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the washing time and kept throughout the experiment (before and after ET-1). NO
donor, Spermine NONOate (100 µmol/L, Cayman Chemical Company, Ann Arbor MI)
was prepared freshly 2 min before adding to the bath. Dibutyryl c-GMP (db-cGMP) was
from ENZO Life Sciences (Ann Arbor, MI). When vardenafil (Bayer AG, Germany) was
used to inhibit PDE5, it was added to the bath during the washing time and was kept
throughout the experiment (before and after NO).
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Figure 14. Measurement of NKCC2
activity in isolated THALs by
A)
fluorescence
microscopy.
Schematic representation of the
experimental design. B) Type of data
collected. NKCC2 activity was
calculated from the initial rate of
increase in intracellular Na when the
luminal solution was exchanged from
0 mmol/L to 130 mmol/NaCl (slope
during initial 20 sec period). Arrow
exemplifies a hypothetical decrease
in NKCC2 activity in the second
period (change in slope).

Na green calibration: THALs were isolated, held between two glass pipettes
and loaded with Na green as explained in section “Measurement of NKCC2 activity” in
the presence of an isosmotic solution containing 3 mM Na in the bath and in the
absence of luminal flow. Na green fluorescence was measured once every 30 sec for
500 msec until basal reading was stable.

Then the bath was exchanged for one

containing 0 mM Na and 400 Units/mL nystatin while acquiring fluorescence
measurements. The solution was allowed to equilibrate for 20 min and then exchanged
for one containing 3 mM Na. The procedure was repeated with solutions containing 6,
12, 24 and 75 mM Na. All solutions contained 400 Units/mL nystatin, were isosmotic
and the concentration of KCl was adjusted for each solution such that [Na+K] = 80 mM.
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The last 5 measurements performed with one solution were averaged and used to
determine the Kd and Bmax of the dye.

We calculated those parameters with the

function one site-total binding using the software GraphPad Prism 5. To account for
differences in dye loading and compare Bmax from 4 different experiments and obtain
one average value, we expressed fluorescence values as fold over fluorescence at 0
mM Na times 1000 (arbitrary units, AU). As expected Kd values were not affected by
this conversion and the background signal was 1.

THAL suspensions: Suspensions were performed as explained in Chapter 2.
cGMP measurements: cGMP was measured using a radioimmunoassay kit
from

Biomedical

Technologies

(Stoughton,

MA)

following

the

manufacturer’s

instructions. Briefly, THAL suspensions were divided in 4 aliquots. Aliquots 1 and 2
were treated with vehicle (perfusion solution) and aliquots 3 and 4 with vardenafil (25
nmol/L) for 10 min. Then aliquots 1 and 3 were treated with vehicle (perfusion solution)
and aliquots 2 and 4 with 100 µmol/L NO donor spermine NONOate (Calbiochem) for
10 min. THALs were lysed with an equal volume of methanol and stored at -80ºC for 2
to 3 hours. Proteins were then spun for 15 min at 15,600g and supernatant* dried
overnight in a concentrator (Savant SpeedVac Plus SC110A). The pellet was stored at
-20ºC for up to 5 days. Several concentrations of cGMP standards were subjected to
the same procedure (dilution in perfusion solution: methanol 1:1 and dried overnight) to
evaluate recovery which was 89 ± 11%. The pellet was resuspended in 120 µL assay
buffer and acetylated overnight by adding 6µL acetic anhydride: triethylamine at 1:2
ratio. Acetylated samples and standards were assayed following the manufacturer’s
instructions.

Control experiments showed that addition of the non-specific

phosphdiesterase inhibitor3-Isobutyl-1-methylxanthine (IBMX increased NO-induced
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cGMP by 6 and 17 fold (incubation with NO for 10 and 20 min respectively).
*Proteins precipitated with methanol were resuspended by mechanical disruption
of the pellet in perfusion solution, vortexing and sonication (10x1 sec, medium power)
and protein concentration measured using a colorimetric assay (Coomassie Plus protein
assay, Pierce, Rockford, IL).

PDE5: Western blots were performed as explained in Chapter 2. Membranes
were blotted in 5% milk-TBST for 1 hr at room temperature and then incubated for 1 hr
with anti-PDE5A1 antibody (BD Transduction, San Jose, CA ) 1:750 dilution, washed
and incubated with 1:1,000 anti-rabbit antibody (GE Healthcare).

Statistical analysis.

Results are expressed as mean ± SE.

Data were

analyzed by the Biostatistics and Research Epidemiology Department of Henry Ford
Hospital. Paired and unpaired t-tests were used as appropriate. When multiple pairwise comparisons were made, Hochberg’s procedure for multiple tests of significance
was applied94.

4. c. Results
First we characterized the method used to measure NKCC2 activity by
calculating the Kd of the dye in our conditions and by estimating the changes in
intracellular Na that occur during the experimental period. We found that the Kd of the
dye was 8.94 ± 2.23 mM Na and that rapid exchange of luminal solution from 0 mM to
134 mM Cl raised intracellular Na from 2.8 to 3.25 mM in 20 seconds (Appendix I).
In normotensive rats, ET-1-induced NO decreases both NKCC2 activity and NaCl
reabsorption77,87 and we have shown that ET-1-induced NO production is impaired in
THALs from Ang II-hypertensive rats (Chapter 2). Thus, we first questioned whether
this translated into impaired ET-1-induced inhibition of NKCC2 activity in Ang II
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hypertension. We found that in vehicle-treated rats ET-1 decreased NKCC2 activity by
38% (from 1.58 ± 0.14 to 0.96 ± 0.16 AU/sec; n= 5; p < 0.04, Figure 15A); however, in
hypertensive rats ET-1’s ability to decrease NKCC2 activity was blunted (∆= - 9%, from
1.46 ± 0.24 to 1.23 ± 0.21 AU/sec; n = 6, Figure 15B). These data indicate that the
ability of physiological stimuli to inhibit NKCC2 activity is impaired in THALs from Ang IIinduced hypertensive rats.
Because superoxide decreases NO bioavailability171 and enhances NKCC2
activity51and our lab has shown that THAL superoxide levels are increased in Ang IIinduced hypertension54, we tested whether the impaired response to ET-1 was due to
elevated superoxide. Acutely scavenging superoxide with 100 µmol/L tempol did not
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Figure 15. NKCC2 activity in response to
ET-1. A) Effect of ET-1 on NKCC2
activity in THAL from vehicle-treated rats
(n = 5; p < 0.04); B) Effect of ET-1 on
NKCC2 activity in THAL from Ang IItreated rats (n= 6; NS); C) Effect of ET-1
on NKCC2 activity in the presence of a
superoxide scavenger in isolated THALs
from Ang II-treated rats. NKCC2 activity
was measured in the presence of 100
µmol/L tempol before and after adding 1
nmol/L ET-1 to the bath (n = 5; NS).
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restore ET-1’s ability to decrease NKCC2 in hypertensive rats (tempol: 1.03 ± 0.18
AU/sec; tempol + ET-1: 1.15 ± 0.20 AU/sec, n = 5 Figure 15C). These data indicate
that acutely, enhanced superoxide levels in Ang II-treated rats are not responsible for
the impaired ability of ET-1 to inhibit NKCC2 activity.
Up to this point our data are consistent with our previous finding that in Ang IIhypertensive rats NO production in response to physiological stimuli is impaired.
However, whether NKCC2 response to NO is also affected is not known. Thus, we next
measured NKCC2 activity in response to the NO donor spermine NONOate. In THALs
from vehicle-treated rats 100 µmol/L spermine NONOate reduced NKCC2 activity by
34%, from 1.68 ± 0.31 to 1.11± 0.31 AU/s (p<0.01, n = 6 Figure 16A). In contrast, NO
was not able to reduce NKCC2 activity in Ang II-treated rats (basal: 1.13 ± 0.17; NO:
1.32 ± 0.23 AU/s, NS, n = 6, Figure 16B). These data indicate that in addition to
reduced NO production, NO-induced inhibition of NKCC2 is blunted in THALs from Ang
II-hypertensive rats.
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Figure 16. Effect of NO on NKCC2 activity. A) Effect of 100 µmol/L spermine NONOate
on NKCC2 activity in THALs from vehicle-treated rats (n = 6); B) Effect of 100 µmol/L
spermine NONOate on NKCC2 activity in THALs from Ang II-treated rats (n = 6).
Impaired NKCC2 inhibition by NO could be due to reduced cGMP production,
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increased cGMP degradation or a defect downstream from cGMP. To test whether the
response to cGMP was also affected in Ang II-treated rats, we measured NKCC2
activity before and after incubation with 500 µmol/L db-cGMP. In vehicle-treated rats,
500 µmol/L db-cGMP reduced NKCC2 activity by 37% from 1.20 ± 0.32 to 0.76 ± 0.27
(p<0.02, n= 5, Figure 17A).

Similarly, in Ang II-treated rats 500 µmol/L db-cGMP

reduced NKCC2 activity by 41%, from 1.15 ± 0.07 to 0.68 ± 0.10 (p<0.035, n = 4, Figure
17B). These data suggest that the signaling cascade downstream from cGMP is intact
in Ang II-induced hypertension.
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Figure 17. Effect of db-cGMP on NKCC2 activity. A) Effect of 500 µmol/L db-cGMP on
NKCC2 activity in THALs from vehicle-treated rats (n = 5); B) Effect of 500 µmol/L dbcGMP on NKCC2 activity in THALs from Ang II-treated rats (n = 4).

Next, we tested whether the defect was due to an impaired ability of NO to
increase cGMP levels. Thus, we measured cGMP in THALs from vehicle and Ang II
hypertensive rats. In the absence of PDE inhibition, basal cGMP levels were low, close
to the detection level and could only be measured in 3 out of 6 experiments in vehicletreated rats (0.21 ± 0.03 fmol/µg protein) and in 2 out of 8 experiments in Ang II-treated
rats (0.20 fmol/µg protein). Incubation with 100 µmol/L NO increased cGMP more in
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THALs from vehicle- than in THALs from Ang II-treated rats (vehicle: 2.24 ± 0.36
fmol/µg pt, n = 6 versus Ang II: 1.22 ± 0.25 fmol/µg pt; n = 8 p<0.04 Figure 18A). These
data indicate that the NO-induced increase in cGMP is impaired in THALs from Ang IIhypertensive rats.
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Figure 18. Effect of NO on cGMP levels:
role of PDE5. A) Effect of 100 µmol/L
spermine NONOate on cGMP levels in
THALs from vehicle- (n = 6) and Ang IItreated rats (n = 8); B) Effect of a PDE5
inhibitor (vardenafil 25 nmol/L) on NOinduced cGMP levels in THALs from
vehicle- (n=6) and Ang II-treated rats (n =
8). C) PDE5 was detected by Western
blot in THAL lysate.

Impaired NO-induced increases in cGMP could be due to reduced production by
guanylate cyclase or increased degradation by PDEs. Since it has been shown that in

vitro, Ang II augments PDE5 activity and cGMP degradation in smooth muscle cells86
and that in vivo Ang II-hypertension enhances PDE5 activity in cardiomyocytes168, we
tested whether inhibition of PDE5 restored NO-induced cGMP in THALs from Ang IIhypertensive rats. First we explored whether PDE5 was present in the THAL. Figure
18C shows a Western blot from THAL lysates depicting a band at the expected

43
molecular weight of 98 KDa corresponding to PDE5. Next we measured cGMP levels.
In the presence of PDE5 inhibition basal cGMP levels were no different between vehicle
and Ang II-treated rats (vehicle: 0.21 ± 0.03 fmol/µg protein, n = 3 versus Ang II: 0.25 ±
0.04 fmol/µg protein, n = 4). However, inhibition of PDE5 restored the ability of NO to
increase cGMP in THALs from Ang II to the same extent than in vehicle-treated rats
(vehicle: 2.07 ± 0.72 fmol/µg protein, n = 6; Ang II: 2.23 ± 0.33 fmol/µg protein, n = 8
NS, Figure 18B). These data indicate that PDE5 blunts NO-induced increases in cGMP
in THALs from Ang II-hypertensive rats.
Finally, we tested whether restoration of NO-induced increases in cGMP by
PDE5 inhibition translated into restoration of NO-induced reduction in NKCC2 activity in
THALs from Ang II-hypertensive rats. In vehicle-treated rats inhibition of PDE5 with 25
nmol/L vardenafil did not affect NO-induced inhibition of NKCC2 (vardenafil: 0.68 ±
0.14; vardenafil + NO: 0.42 ± 0.16 AU/sec, 38% inhibition, p< 0.02, n=4, Figure 19 A).
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Figure 19. Effect of NO in the presence of a PDE5 inhibitor on NKCC2 activity. A) Effect
of 100 µmol/L Spermine NONOate in the presence of a PDE5 inhibitor (vardenafil 25
nmol/L) on NKCC2 activity in THALs from vehicle-treated rats (n= 4); B) Effect of 100
µmol/L Spermine NONOate in the presence of a PDE5 inhibitor (vardenafil 25 nmol/L) on
NKCC2 activity in THALs from Ang II-treated rats (n=5).
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However, in Ang II-treated rats, inhibition of PDE5 restored the ability of NO to reduce
NKCC2 activity (vardenafil: 1.17 ± 0.23; vardenafil + NO: 0.43 ± 0.1 AU/sec, 63%
inhibition, p<0.02, n=5, Figure 19B). Time controls with vardenafil showed no difference
between first and second period (first period: 0.67 ± 0.15 AU/sec; second period: 0.67 ±
0.03 AU/sec). Altogether these data indicate that PDE5 blunts NO-induced increases in
cGMP and inhibition of NKCC2 activity in THALs from Ang II-hypertensive rats.

4. d. Discussion
In this work we found that ET-1-induced inhibition of NKCC2 activity is impaired
and that PDE5 blunts NO-induced increases in cGMP and inhibition of NKCC2 activity
in THALs from Ang II hypertensive rats (Figure 20). This conclusion is based on the
following findings: 1) ET-1-induced inhibition of NKCC2 activity was reduced in THALs
from Ang II-hypertensive rats and this was not due to acute increases in superoxide
levels; 2) NO-induced inhibition of NKCC2 activity was also impaired in THALs from Ang
II-hypertensive rats; 3) db-cGMP inhibited NKCC2 activity to the same extent in Ang IIand vehicle-treated rats; 4) NO-induced increases in cGMP was impaired in THALs
from Ang II-hypertensive rats and this was restored by inhibiting PDE5 and 5) NOinduced decreases in NKCC2 activity was restored in THALs from Ang II-hypertensive
rats by inhibiting PDE5.

To our knowledge this is the first time that impaired NO-

induced inhibition of Na reabsorption has been shown in Ang II-induced hypertension.
Moreover, this is the first time that PDE5 has been shown to play a role in THAL NaCl
reabsorption during Ang II-hypertension.
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Chapter 4. In THALs NO inhibits
NKCC2 activity via cGMP. In Ang IIhypertensive rats, PDE5 blunts NOinduced increases in cGMP and
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ET-1 inhibits NKCC2 by increasing NO, which reduces the number of
cotransporters in the luminal membrane via cyclic GMP77,160. We have found that in
Ang II-induced hypertension, physiological stimuli such as ET-1 and PIP3 cannot elicit
increases in NO production in THALs and that the defect is related to reductions in
NOS3 expression and phosphorylation at the stimulatory site serine 1177 (Chapter 2).
However, mechanisms that increase cGMP formation or sensitivity to NO could
maintain normal ET-1-induced inhibition of NKCC2. Nevertheless, our findings indicate
this is not the case, as impaired ET-1-induced NO production translated to blunted ET1-induced inhibition of NKCC2.
Since ET-1 is an important regulator of blood pressure and NaCl reabsorption by
the kidney and the THAL120,172, we focused on the ability of this hormone to inhibit
NKCC2 activity during hypertension. We found that ET-1-induced inhibition of NKCC2
is impaired in THALs from Ang II hypertensive rats and that this correlates with impaired
NO production.
Superoxide levels are increased in many models of hypertension54,173.

In

particular, Ang II acutely and chronically elevates superoxide formation by the THAL50,54
and superoxide not only reduces NO bioavailability but also directly stimulates NKCC2
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activity51,171,174. We found that acute superoxide scavenging did not restore the ability of
ET-1 to inhibit NKCC2, suggesting that superoxide does not acutely mediate impaired
ET-1-induced reduction in NKCC2 activity. This is in contrast to a previous report that
showing that chronic infusion of the superoxide scavenger tempol reduced basal NaCl
transport by THALs from Ang II-induced hypertensive rats54. However, in that study
tempol was infused chronically throughout Ang II treatment and basal NaCl reabsorption
rather than the response to ET-1 was studied. Interestingly, we have shown that in vitro
chronic Ang II decreased NOS3 expression in THAL primary cultures and this was
prevented by chronic tempol treatment (Chapter 3). Therefore, it is likely that chronic
exposure to elevated superoxide mediates the Ang II-induced decrease in NOS3, which
ultimately fails to produce NO and inhibit NKCC2 in response to ET-1.
In our lab it was shown that superoxide increases NKCC2 activity51, that Ang IIhypertension augments superoxide54 and that scavenging superoxide enhances Larginine-induced increases in NO production and inhibition of NaCl reabsorption by the
THAL171. Thus, it is possible that tempol treatment reduced basal NKCC2 activity in
THALs from Ang II-hypertensive rats. However, the purpose of our experiment was to
test whether the increased superoxide production was responsible for the impaired
response to ET-1, either by scavenging ET-1-induced NO or by activating PKC. Our
data indicate that acutely, superoxide is not responsible for the defective ET-1-induceddecreases in NKCC2 activity.
Impaired inhibitory response to ET-1 could also be due to reduced response to
NO. Our lab has shown that in Dahl salt-sensitive rats, NO-induced inhibition of NaCl
reabsorption is decreased21. Therefore, we explored whether the signaling cascade
downstream from NO was also affected. Similar to what was found in Dahl salt-sensitive

47
rats, the ability of NO to inhibit NKCC2 activity was impaired in THALs from Ang II
hypertensive rats. Resistance to NO donors has also been found in glomeruli of Ang IIhypertensive rats, where cGMP levels in response to sodium nitroprusside was
decreased; however, the authors attributed this defect to reduced cGMP production
rather than enhanced degradation175. Thus to our knowledge this is the first time that
impaired response to a NO donor has been shown in any nephron segment in Ang IIinduced hypertension.
In order to dissect the mechanism by which Ang II-hypertension blunts the ability
of NO to inhibit NKCC2 activity we first studied the response to the cGMP analog dbcGMP. We found that treatment with 500 µmol/L db-cGMP inhibited NKCC2 to the
same extent in normotensive and hypertensive rats indicating that the signaling cascade
downstream from cGMP is intact in Ang II-treated rats. cGMP inhibits NKCC2 activity in
part by stimulating PDE2, which degrades cAMP160. Since cAMP levels are important
for the maintenance of normal NKCC2 levels at the plasma membrane176,177, activation
of PDE2 decreases cAMP and reduces NKCC2 at the surface. However, our data
suggest that these processes are intact in THALs from Ang II-hypertensive rats.
In our experiments, we used 500 µmol/L db-cGMP because at this dose this
analog reduces NKCC2 levels at the plasma level by about 45%

160

. Although it seems

a high concentration, it has been shown that only about 10% of cyclic nucleotide
analogs (with similar permeabilities than db-cGMP) applied extracellularly could be seen
inside the cell178 and thus, intracellular db-cGMP would be about 50 µmol/L.
Considering that the Km of PDE2 for cGMP is about 10-31 µmol/L

85,179

, we believe that

the concentration of db-cGMP we used was appropriate to test the effect of cGMP on
NKCC2 activity.
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Since the response to cGMP was intact, we next explored whether the defect
was due to an inability of THALs from Ang II-treated rats to augment cGMP levels in
response to NO. We found that treating THALs with a NO donor increased cGMP
levels to a lower extent in THALs from Ang II-hypertensive rats compared with vehicletreated rats. These data indicate that either cGMP production was reduced or that
cGMP degradation was enhanced.
cGMP could be degraded by cGMP-specific PDEs like PDE5, PDE6 and PDE9
or PDEs with dual-specificity like PDE1, 2, 3, 10 and 11 83. Since Ang II increases PDE5
expression and activity in smooth muscle cells86 we focused on PDE5. In order to study
whether PDE5 was present in THALs we performed Western blots of THAL lysates. We
found a single band at the expected molecular weight of 98 KDa. The presence of
PDE5 in the kidney has been shown before but it was found in proximal tubules and
collecting ducts166,180. Similar to our findings, Dr. Ortiz’s lab has shown the presence of
PDE5 in THALs (personal communication) confirming our findings that PDE5 is
expressed by this nephron segment.
To test whether PDE5 was responsible for reduced cGMP levels in response to
NO we treated THALs with the PDE5 inhibitor vardenafil. We found that in the presence
of vardenafil, NO stimulated cGMP to the same extent in normotensive and
hypertensive rats.

Altogether, these data indicate that PDE5 blunts NO-induced

increases in cGMP in THALs from Ang II-hypertensive rats. Notably, basal cGMP levels,
in the presence or absence of vardenafil, were not different between normotensive and
hypertensive rats suggesting that basal PDE5 activity is insignificant and that only after
cGMP levels rise, PDE5 activity increases in Ang II-hypertensive rats.

In addition,

inhibition of PDE5 with 25 nmol/L vardenafil did not affect NO-induced increases in
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cGMP levels in vehicle-treated rats indicating that even in the presence of high cGMP
levels, PDE5 activity in THALs from normotensive rats remains negligible.
We used vardenafil to inhibit PDE5 because it is very specific and is the most
potent PDE5 inhibitor on the market, being more than 10 times more potent than
sildenafil and taldalafil181. The EC50 for PDE5 is about 0.4 nmol/L181 and, except for
PDE6A and B, is at least 500 times more selective for PDE5 than for any other PDE
discovered so far182. At the concentration used in this study (25 nmol/L) only PDE5 and
PDE6 would be inhibited; however, PDE6 has only been found in the retinal
photoreceptors, pineal gland and in some melanoma cells83 but not in the kidney. Thus,
our data strongly indicate that PDE5 is the PDE responsible for enhanced cGMP
degradation in THALs from Ang II hypertensive rats.
Finally, we explored whether inhibition of PDE5 would restore the ability of NO to
inhibit NKCC2 activity. Blockade of PDE5 with 25 nmol/L vardenafil did not enhance
NO-induced inhibition of NKCC2 activity in vehicle-treated rats, but it did restore the
ability of NO to reduce NKCC2 activity in Ang II-treated rats. These data indicate that in
THALs from Ang II-hypertensive rats PDE5 blunts NO-induced inhibition of NKCC2
activity.
A similar finding has been shown in pregnant rats in which the natriuretic
response to a NO donor was only observed in the presence of PDE5 inhibition165.
Analogous to our results in hypertension, inhibition of PDE5 in inner medullary collecting
ducts from pregnant rats also restored the ability of NO donors to increase cGMP levels
to the same extent as in non-pregnant rats. However, in contrast to our findings, PDE5
inhibition by itself enhanced Na excretion in pregnant rats.

Altogether these data

indicate that during pregnancy, NO and cGMP levels in the kidney are increased but
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their actions are limited by PDE5 whereas in THALs from Ang II hypertensive rats NO
levels are reduced even in response to physiological stimuli and thus enhanced PDE5mediated degradation of cGMP is only observed in the presence of exogenous NO.
Based on our results we can speculate that inhibition of PDE5 alone would not enhance
natriuresis in hypertension and thus a combined therapy that simultaneously restores
NOS3 activity and inhibits PDE5 in the kidney would be needed to restore the ability of
the kidney to properly respond to natriuretic hormones.
In conclusion, in Ang II-induced hypertension PDE5 blunts NO-induced increases
in cGMP and inhibition of NKCC2 activity in THALs.

The inability of the THAL to

respond to this important natriuretic factor likely contributes to the inappropriately
enhanced NaCl reabsorption observed in this model of hypertension.
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CHAPTER 5
FINAL REMARKS
5. a. Summary
In this work we investigated the response of THALs from Ang II-hypertensive rats
to physiological stimuli known to increase NO production and inhibit NKCC2 activity in
normotensive rats (Figure 21). We found that in THALs:
1-

NO production in response to ET-1- and PIP3 is blunted in Ang II-hypertensive
rats and this correlates with reduced NOS3 expression and impaired PIP3induced increases in NOS3 phosphorylation at serine 1177 (Chapter 2).

2-

The effect on NOS3 expression is due to a direct effect of Ang II rather than a
consequence of changes occurring in vivo (Chapter 3).

3-

Ang II-induced reduction in NOS3 expression is mediated by both NO and
superoxide and thus is likely due to peroxynitrite (Chapter 3).

4-

ET-1-induced inhibition of NKCC2 activity is blunted in Ang II-hypertensive rats
and this is not due to acute increases in superoxide production (Chapter 4).

5-

NO-induced increases in cGMP and inhibition of NKCC2 activity are also
impaired in Ang II-induced hypertension and this can be reversed by PDE5
inhibition (Chapter 4).

NOS3

ETB ET-1

pNOS3
NO

NaCl
Na
K
2Cl

Apical

cGMP

Ang IIhypertension

PDE5
GMP

Basolateral

Figure 21. Summary of results. In
THALs from normotensive rats ET-1
inhbits NKCC2 activity via NO and
cGMP. In Ang II-hypertensive rats
this response is impaired due to 1)
reduced NOS3 expression and
phosphorylation at serine 1177, 2)
decreased
stimuli-induced
NO
production and 3) enhanced cGMP
degradation by PDE5.
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5. b. Limitations of the study
Although the methods we used are generally known as being state of the art at
this time, we recognize that they have limitations. Here we discuss some of them.
As a general limitation, the use of rodents as a model of human diseases implies
that such animals will respond to treatments in the same way that humans do. Although
there are high similarities in the physiology of humans and rats, there are many genes
that are not expressed in both species and others that have different regulation.
However, we believe the use of animals is necessary as a first approach to investigate
new signaling mechanisms involved in any pathology.
Another limitation is the age of the rats used. In order to facilitate THAL
dissection, we used young rats; however, hypertension usually develops in older
subjects and thus the mechanisms involved in the maintenance of high blood pressure
could be different.
In this work we studied the response to different treatments of either isolated
THALs or THAL suspensions. As with any research performed in vitro, there are a
number of advantages as well as disadvantages compared to in vivo and whole-animal
research. Some intrinsic limitations are:
5. b. i. Isolated THALs are studied on a glass chamber outside the renal and
body environment, devoid of any interaction with other renal structures, nervous input
as well as hormones and autacoids normally present.

However, the ability to use

isolated and perfused THAL allows us to study THAL function in response to specific
stimuli.
5. b. ii. THALs are perfused in a chamber with continuous exchange of the
basolateral solution. This maneuver likely washes out some of the autacoids released
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by this nephron segment, and thus such responses are missed.

However, the

basolateral bath in which THALs are kept is continuously exchanged to ensure that
appropriate oxygen and nutrient levels are delivered throughout the experiment.
5. b. iii. We studied the response of one stimulus at the time when in reality
simultaneous presence of different hormones, metabolites and autacoids likely interact
affecting the final result. We did this with the purpose of taking a more practical and
easier to analyze approach.
5. b. iv. The osmolality of the basolateral solution was 290 mOsm/L when the
osmolality of the outer medulla is about 360 mM183. However, given that the osmolality
changes with salt-intake and that we wanted to compare our results to those found by
others, we used 290 mOsm/L184-187.
5. b. v. In THAL suspensions, although at low percentage (8%), there is still
presence of some cells from other nephron segments.

However, at the present

moment, this is the best way to study THAL protein expression or production of lowabundance metabolites like cGMP.
5. b. vi. Measurements of NO and NKCC2 activity were done using a single
wavelength fluorescent dye. Measurements performed with this type of dye are more
susceptible to changes in light intensity, cell volume and dye loading. To avoid some of
those problems, we only compared measurements done in the same tubule (not
between different tubules), we standardized all our measurements, and we confirmed
our findings with other type of experiments (e.g. measurement of NOS3 phosphorylation
or cGMP levels).

This limitation of the technique also prevented us from studying

whether basal NO production and NKCC2 activity were different in THALs from
normotensive and hypertensive rats.
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5. b. vii. Measurements of NKCC2 activity were done based on the assumption
that Na/K ATPase activity was negligible (appendix I); however, such measurements
were not made. Therefore, there is a possibility that Na/K ATPase activity could have
significantly affected the rate of increase in intracellular Na and that the NKCC2 activity
values reported here are lower than the real one.
5. b. viii. Calibration of Na green was done in the presence of nystatin at varying
concentrations of Na such that [Na] + [K] = 80 mmol/L and the obtained Kd was about 9
mmol/L. This Kd value is lower than the one previously reported in response to varying
concentrations of Na when [Na] + [K] = 135 mol/L. Since K interferes with Na
measurement by NaGreen, using a lower than real [K] could lead to an apparent Kd
lower than real. However, in contrast to some cells where intracellular K can reach up to
140 mM, in THALs intracellular K has been shown to vary between 80 mmol/L
117 mmol/L

189

188

and

. Furthermore, Despa et al. found that the Kd of NaGreen measured in

HeLa cells by lifetime microscopy was 9 mmol/L when using solutions containing
[Na]+[K]= 145 mmol/L and that the Kd increased to 21 mmol/L in the presence of
albumin 190. Since our experiments were run in the absence of albumin our values are in
agreement with those published in such conditions, and thus we believe it is safe to
conclude that the Kd of NaGreen in our system was about 9 mmol/L.
5. b. ix. Stimulation of THALs with ET-1 and PIP3 were done only at one
concentration; thus, it is not clear whether there is a shift to the right in the response to
these stimuli, in which case higher concentrations would give different results. We
chose 1 nmol/L ET-1 based on previous data showing that maximum stimulation of
NOS3 and inhibition of THAL NaCl transport in normotensive rats were achieved at this
concentration

77,87

. With regard to PIP3 we used a concentration of PIP3 that was 2
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orders of magnitude higher than the Km of PIP3 binding to Akt (the enzyme activated by
PIP3)191 to maximally stimulate Akt. Nevertheless, it has been shown that interstitial
ET-1 levels in the outer medulla of Ang II-hypertensive rats is not different from control
rats suggesting that increases in ET-1 levels do not likely compensate for the impaired
response in hypertension. Finally, enhanced PIP3 production in response to ET-1 does
not likely play a role since the response to ET-1 was blunted as well.
We studied ETB receptor expression levels by Western blot. However, ET-1
binding to ETB receptors could also be affected. ETB receptor function also depends on
its presence at the plasma membrane and on its phosphorylation state192. However, we
do not believe changes in ETB receptor function are likely to be the explanation to
reduced NO production since stimulation of THALs with PIP3 also failed to increase NO
levels.
Although we believe the reduction in NO production was due to decreases in
NOS3 expression and NOS3 phosphorylation we cannot exclude the possibility that
other factors such as NOS uncoupling, changes in NOS3 protein-protein interactions,
NOS3 localization, etc also contribute to impaired NO production. Ideally, restoration of
NOS3 expression in the THAL via trans-gene expression in Ang II-hypertensive rats
would answer the question of whether reductions in NOS3 expression are the only
cause of decreases in NO production.

In order to know whether impaired

phosphorylation of NOS3 in response to PIP3 is the cause of such a defect, we first
need to identify the cause of that impairment.
We found that reduced NO production in response to physiological stimuli and
increased PDE5-mediated degradation of cGMP were responsible for impaired
inhibition of NKCC2 and likely contribute to the elevation in blood pressure in this model
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of hypertension.

However, we did not test this.

THALs are not the only tissue

responsible for the elevation of blood pressure in Ang II-hypertension. The THAL’s
contribution to the increase in blood pressure is likely to be at most 30% (6 mmHg in our
model). To extrapolate our results to blood pressure regulation, it would be necessary
to perform 1) a THAL-specific inducible-knock down of NOS3 and overactivation of
PDE5 and measure blood pressure by telemetry or 2) THAL-specific inducible NOS3
overexpression and PDE5 silencing and study the change in blood pressure in
response to Ang II.

5. c. Perspectives
Ang II-induced hypertension has long been used as a model of human
hypertension. Although this model has been extensively studied, the mechanisms by
which Ang II increases blood pressure have not been completely elucidated.
The role of the kidney in general and the THAL in particular in the regulation of
blood pressure is well established, showing that inappropriately elevated NaCl
reabsorption is present in hypertension. On one hand, NO produced by NOS3 inhibits
THAL NaCl transport and mediates the effect of many natriuretic stimuli. On the other
hand, decreases in NO production and impaired response to NO in the renal medulla
have been shown in salt-sensitive hypertension. Altogether these data indicate that
defects in THAL NO production and actions could also be present in Ang IIhypertension.
In the first part of this work, we showed that chronic Ang II infusion decreases
NOS3 expression, impairs NOS3 phosphorylation and reduces stimuli-induced NO
production, thus suppressing an important physiological signaling cascade that
mediates natriuresis. These findings not only add to previous data showing impaired
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natriuresis in hypertension but also propose another defective pathway present in these
subjects: reduced THAL NOS3 expression. Decreased NOS3 expression induced by
Ang II may be one of the mechanisms by which this hormone enhances Na retention.
In addition, these results predict that natriuretic hormones or drugs that depend on NO
as a mediator will fail to increase NaCl excretion and imply that some of the beneficial
effects of Ang II receptor blockers and angiotensin converting enzyme inhibitors could
be due to normalization of NOS3 expression and NO production.
In the second part of our study we explored the signaling mechanism by which
Ang II reduces NOS3 expression. In order to directly test the effect of Ang II on NOS3
expression and avoid the confounding effect associated with elevations of Ang II in vivo
we performed the study in THAL primary cultures. We found that Ang II decreases
NOS3 expression in THALs via NO and superoxide, raising the possibility that
peroxynitrite is involved.
Our lab has previously shown that chronic infusion of the superoxide scavenger
tempol into the renal medulla decreases NaCl transport by the THAL in Ang IIhypertensive rats, suggesting that this treatment could restore NOS3 expression and
NO production. The effect of Ang II in the THAL is opposite from the findings previously
shown in the renal cortex and endothelial cells193, highlighting the importance of
studying the response by each cell type. Understanding the uniqueness of the effect of
Ang II in each nephron segment and discerning the pathways that lead to an imbalance
between pro and anti-oxidant species would allow for the design of better drugs for the
treatment of hypertension.
NO inhibits THAL NaCl reabsorption by inhibiting NKCC2. This cotransporter is
not only responsible for all transcellular Cl transport but is instrumental in determining
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the lumen-to bath positive potential, which generates the driving force for paracellular
cation reabsorption6,16. Hormones such as ET-1 stimulate NO production and inhibit
NaCl transport primarily by decreasing NKCC2 activity in normotensive rats77 and
elevations in THAL NaCl reabsorption and NKCC2 activity have been found in
hypertension19-21,23,54,194-196. However, whether regulation of NKCC2 activity by ET-1 is
impaired in Ang II-induced hypertension has not been shown before.
In the last part of our work, we found that in addition to reductions in NO
production, ET-1-induced inhibition of NKCC2 activity was also blunted in Ang IIhypertension and this was not reversed by acute superoxide scavenging. Moreover,
when exploring the response to NO, we found that it was also reduced. NO-induced
increases in cGMP as well as NO-induced inhibition of NKCC2 activity were blunted in
THALs from Ang II-hypertensive rats and such responses were restored by inhibiting
PDE5. Thus, we demonstrated that in THALs from Ang II-induced hypertensive rats
PDE5 blunts the ability of NO to increase cGMP and inhibit NKCC2 activity.
The effect of PDE5 in hypertension has been studied before, and PDE5 inhibitors
are being used to treat heart failure and pulmonary hypertension162,163; however,
whether their effectiveness is, at least in part, due to increased Na excretion by the
kidney and whether PDE5 inhibitors would reduce blood pressure in other types of
hypertension is not clear. Unfortunately, the high expression of PDE5 in other tissues
makes this treatment very nonspecific, so discovering the signaling mechanisms that
lead to enhanced THAL PDE5 activity during hypertension would be important in
designing new drugs for the treatment of high blood pressure.
Finally, if we extrapolate our findings in the THAL to the whole kidney, we would
predict that PDE5 inhibitors alone would not be useful in reducing Na retention and
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decreasing blood pressure in hypertension. Our data indicate that in Ang II-induced
hypertension redundant mechanisms that impair Na excretion by the THAL are present:
reduction in NO production in response to physiological stimuli and increased cGMP
degradation. Thus, a combination therapy that augments both renal NOS3 expression
and activity (like statins and Rho kinase inhibitors) together with PDE5 inhibitors could
be effective in enhancing Na excretion and restoring blood pressure to normal values.
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APPENDIX I
Calculations of Intracellular Na during Measurements of NKCC2 Activity
In order to validate the method used to measure NKCC2 activity in isolated
THALs we calculated the intracellular Na concentration during the measurement. We
estimated intracellular Na concentration based on measurements of the dissociation
constant of the dye (Kd) and the maximal binding capacity of the dye (Bmax).

I. a. Calculation of intracellular Na

Definitions:
FU0: Fluorescence at the time when luminal solution is changed from low (0 mM)
to high (135 mM) NaCl, first data point in the calculation of the slope of increase in
intracellular Na or NKCC2 activity.
AU: Arbitrary units calculated as FU/FU0*1000.

Approximations:
To calculate Kd and Bmax, total Na was used as a surrogate for free Na. This
was done because with the present technology is not possible to separate Na bound to
the dye from free Na in an isolated and perfused tubule.

Calculations:
Intracellular Na values were calculated from our data collected in experiments
and the calibration of the dye. From calibration experiments we found that Bmax was
0.823 ± 0.017 AU/AU0 (after subtracting 1.000 ± 0.002 AU/AU0 for background), Kd was
8.94 ± 2.23 mM Na and non specific binding was 0.003 ± 0.001 AU/AU0. Since nonspecific binding is negligible (less than 3% of the total binding used to estimate Na) we
did not include it in our calculations.
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Figure A I. Na green calibration.
Cumulative data of 4 experiments
showing the change in AU in response
to changes in intracellular Na.
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The constant of dissociation of [NaDye] into [Na] and [Dye] can be represented as

    

Where [Na]f = free intracellular Na
[Dye]f = free intracellular Dye
[NaDye]= intracellular Na-Dye complex
The intracellular concentration of [Dye]f is not known; however, we can estimate
it from the calibration curve by assuming that at Bmax the maximum available binding
sites are bound and thus Bmax could be used as total [Dye].
Considering that
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Based on our NKCC2 experiments, increases in intracellular Na when luminal
solution changes from 0 mM NaCl to 135 mM Na reaches a plateau and thus likely a
steady state condition when fluorescence is 1.30 ± 0.04 AU/AU0, which occurs about 6
minutes after the switch. Thus, based in experiments done in our lab showing that in
THALs intracellular Na is 13.5 mM66 we can calculate theoretical [NaDye] in AU/AU0
units



0.823 %&/%&0  13.5 *
8.94 *  13.5 *

0.495 -&/-&0

then at 13.5 mM Na, Fluorescence should be

0.495 -&/-&0  1 -&/-&0 . /0123.45

1.495 -&/-&0.

Since our steady state condition is equal to 1.30 AU/AU0 these data indicate that
during THAL perfusion with low Na solution intracellular Na is higher than 0 mM. To
calculate this value we substracted 1.30 AU/AU0 (value achieved in plateau during our
experiment and expected to be 13.5 mM) to 1.495 AU/AU0 (value that should have been
read in the case that the intracellular Na0 was 0 mM).

1.495  1.30 -&/-&0

0.195 -&/-&0

Therefore, we used 0.195 AU/AU0 as a “real” initial value to calculate the
concentration of intracellular Na during tubule perfusion with low Na solution.
Rearranging equation (1) and calculating:

61 –

8.9:; <=/<=8

A  

8.>?@ <=/<=8



8.9:; <=/<=8 >.:B C
8.>?@ <=/<=8

2.78 *

(2)
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Thus, intracellular Na in the THAL during perfusion with low Na is about 2.78
mM.
Next we questioned what the intracellular Na concentration at the end of the 20
seconds period used to measure NKCC2 activity was. In our experiments, the slope of
increase in AU during the 20 sec period varied between 0.9 and 1.68 AU/sec. Thus, the
increase in fluorescence from time 0 to 20 seconds varied from 0.018 to 0.033 AU. If
we add that to our 0.195 AU “real” value we can calculate intracellular Na after 20 sec
perfusion with high Na solution.

Similar to (2)

E1 –

0.213 -&/-&0  8.94 *
0.823 -&/-&0

0.213 -&/-&0
F  
0.823 -&/-&0


E1 –

3.12 *

0.228 -&/-&0
F  
0.823 -&/-&0


0.228 -&/-&0  8.94 *
0.823 -&/-&0
3.42 *

Therefore, at the end of the 20 seconds period intracellular Na would be about
3.1 to 3.4 mM (average 3.25 mM).
Assuming that no post-translational changes occur during this maneuver Na/K
ATPase activity can be described by the following model of cation binding described by
Garay and Garrahan 197

G

G
1  ′′ ′
 H
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Where KNa represents the apparent affinity for Na and n represents the number
of binding sites, in the case of Na and the Na K ATPase, n=3
Since we do not know KNa, we first calculated that value considering that:
V= ½ Vmax when [Na]= 9.5 mM

198-201

Therefore KNa

1
G
2

G
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 @
A
9.5

J

J

√9.5

√ 


2.12 *

Considering KNa of 2.12 mM we calculated the velocity of the pump at [Na] =
2.78 mM.

G

G

61 
G

2.12* @
2.78* A

0.18 G

Calculating the same velocity but using 3.42 mM Na as the highest velocity the
pump would have in our measurement we find that

G

0.24 G

Averaging both values to calculate a mean pump velocity during the 20 second
period we have

G

0.21 G .3 21% G
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Therefore, NaK ATPase activity will vary from 18% to 24% of Vmax during the
course of the experiment. However, the ability of the Na/K ATPase to pump Na against
its electrochemical gradient depends on the pump electromotive force (Emf) and the
electrochemical driving force (VDF) for Na at any given condition. Considering

G%
where

G  GLM

Vm= membrane potential
VEq= equilibrium potential
And THAL basolateral Vm = -65 mV 202

Therefore, in basal conditions

GLM 

NO
 .
 ln
P%
 S

61.5 log

135*
13*

62.5 G

and

G% 

65 G  62.5

127.5 G

Since the electromotive force of the Na/K ATPase has been estimated to be
between 137 mV11 and 170 mV 203 at Vm of about -65 mV. These results indicate that in
basal conditions (when tubule is perfused with 135 mM NaCl), the electrochemical
driving force for Na is lower than the Na/K ATPase pump electromotive force and thus,
Na is pumped out of the cell.
However, in conditions where NaCl entry is blocked by perfusing the THAL with a
solution containing 0 mM NaCl plus amiloride (Na/H exchanger inhibitor), the VEq[Na]
would be:

GLM 

61.5 log

135*
3 *

102 G
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If we consider that perfusing the THAL with 0 mM NaCl has a similar effect on
the basolateral membrane potential as the treatment with furosemide (NKCC2 inhibitor),
then basolateral membrane potential would decrease by about 15 mV199,200 and the
VDF[Na] at 0 mM luminal NaCl would be:

G% 

80 G  102

182 G

Although some groups have shown that Na/K ATPase EMF does not depend on
Vm

202

203

(the equation considers the change from Vm=0 to the final value in the

others have shown that EMF varies with Vm according to the following equation

hyperpolarizing direction):

L*%

134  0.56 ∆G

Therefore, at a Vm of -80mV, EMF will have a value between 135 and 178 mV.
However, the VDF for Na would be higher than the Na/K ATPase EMF and thus the
pump velocity will likely be very low.

I. b. Conclusions
We estimated that during the measurement of NKCC2 activity intracellular Na
increased from 2.8 mM after 20 min of perfusion with a solution containing 0 mM NaCl
to about 3.4 mM after 20 sec of perfusion with a 130 mM NaCl solution. We also
estimated that the Na/K ATPase activity during this maneuver should have been below
21% of maximum activity but likely negligible.
To make these calculations we have used several assumptions and
approximations. For example we assumed that total Na could be used as a surrogate of
free Na. This approximation would only be correct when Na<<< to Km. However, with
the methodology available we cannot separate Na bound to the dye from free Na. This
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approach has been widely used since calibrations of fluorescent dyes also base their
measurements in this assumption

190,204

. We also assumed that steady-state Nai was

13.5 mM. Although we did not measure intracellular Na in steady state conditions we
made this approximation based in previous results from THALs obtained in our lab and
therefore we are confident that such values are within the range of intracellular Na
present in THALs. Another approximation we made was that the EMF of the pump and
the membrane potential was the same as the one recorded in toad bladder. Na/K
ATPase EMF has been shown to vary between 135 and 178 mV

202,203

and although

some reports show variation with membrane potential others claim that EMF is not
affected. Nevertheless it is estimated that at [Na] on the mucosal side of 6 mM or lower
Na flux becomes close to 0 in toad bladder

202

suggesting that imposing a steep

electrochemical gradient significantly reduces the Na/K ATPase activity to transport Na
out of the cell. Although those values can change depending on the conditions used, we
believe it is safe to conclude that the Na/K ATP activity will be minimal after 20 min of
inhibition of NKCC2 activity by perfusing THALs with 0 mM NaCl based on the following
additional evidence: 1) Greger demonstrated that intracellular Na in the presence of
NKCC2 inhibition was about 5 mM and that under those conditions Na/K ATPase
activity was very low 6; 2) after NKCC2 inhibition, ouabain does not reduce oxygen
comsumption any further suggesting that Na/K ATPase activity in the absence of
NKCC2 activity is minimal

205

; 3), in basal conditions ouabain depolarizes THAL cells

and induces cell swelling; however, in the presence of furosemide, ouabain does not
affect membrane potential or cell volume

6,206

indicating that in the presence of NKCC2

inhibition Na/K ATPase activity is negligible.
Finally, although our estimations indicate that Na/K ATPase activity in the
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presence of NKCC2 and NHE3 inhibition would be negligible, there is a possibility that
this is not true. If that were the case we expect that the Na/K ATPase activity effect on
the measurement of NKCC2 activity is likely to not affect the change in NKCC2 activity
observed in response to the acute treatments since we have shown that NO 66 does not
affect Na/K ATPase activity in THALs. However, we recognize that in order to ensure
this, it would be necessary to measure Na/K ATPase activity in those conditions or to
measure changes in intracellular Na in response to ouabain when the THAL is perfused
with a solution containing 0 mM NaCl in the presence of dimethyl-amiloride. Absence of
any change in intracellular Na would indicate that the Na/K ATPase activity is negligible
and thus prove our assumption correct.
In conclusion we believe that measurement of NKCC2 activity monitoring
intracellular Na with the fluorescent dye Na green in response to changes in luminal
NaCl concentrations is a reliable method to study the activity of this co-transporter in the
THAL.
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APPENDIX II
Protocol Approval
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Cardiovascular disease is the leading cause of death in the US. Hypertension,
which affects about 30 % of the US population, is an important risk factor in the
development of this disease. Inappropriately elevated sodium reabsorption by the
kidney contributes to hypertension; therefore, studying the mechanisms that lead to
enhanced sodium transport is important in understanding this pathology.

The thick

ascending limb (THAL) reabsorbs 30% of the filtered sodium chloride load. Nitric oxide
(NO) produced by NO synthase type 3 (NOS3) increases cyclic GMP (cGMP) and
inhibits THAL transport by reducing Na/K/2Cl cotransporter type 2 (NKCC2) activity.
Interestingly, in angiotensin II-induced hypertension, THAL NaCl transport is enhanced.
However, whether this is due to a direct effect of angiotensin II on the transporters or to
a defect in the NO-signaling pathway is not known. We hypothesized that THAL NO
production and inhibition of NKCC2 activity are impaired in angiotensin II-hypertension.
We used THALs from normotensive and angiotensin II-infused hypertensive rats. We
found that:
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1) THAL NO production in response to physiological stimuli was decreased and
this correlated with reduced NOS3 expression and phosphorylation at serine 1177 in
angiotensin II-induced hypertension;
2) the effect of angiotensin II on NOS3 expression was mediated by peroxynitrite;
3) NO-induced increases in cGMP and inhibition of NKCC2 activity were
impaired in angiotensin II-hypertension and this was restored by inhibition of
phosphodiesterase 5.
In conclusion, we found that in angiotensin II-induced hypertension THAL NO
production is reduced and NO-induced inhibition of NKCC2 activity is blunted due to
increased phosphodiesterase 5 activity.

We believe this could be one of the

mechanisms by which angiotensin II increases NaCl transport by this nephron segment
and that treatments that simultaneously increase NO production and inhibit
phosphodiesterase 5 activity in the kidney could be useful in the management of
hypertension.
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